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The lack of good preclinical models has hampered anticancer drug discovery. Standard 
preclinical protocols require the growth of cells in high throughput two-dimensional (2D) culture 
systems. Such in vitro drug testing methods yield drug efficacy results that differ greatly from 
animal models. Yet, despite giving a more accurate morphological representation of tumor 
development, it is much more difficult and expensive to use animal models for large-scale 
molecular biology research. Furthermore, despite being synergetic, typical animal models cannot 
be controlled for all biological modulators and can result in biological variability in relation to 
tumor engraftment and consequently drug efficacy. It is conceivable that three-dimensional (3D) 
growth may be responsible for some of these changes and that such growth may form a 
reproducible and more representative step in tumoricidal validation prior to animal implantation, 
thus, saving on cost and animal sacrifice, and indeed possibly obviating the need for animal 
testing. Moreover, culturing 3D tumor constructs in a bioreactor would combine the advantages 
of the 2D and xenograft models, making it possible to study the effects of the supporting stroma 
and interstitial fluid modulators like pressure on cancer cell behavior, and potentially carry out 
high throughput anticancer drug screening.  
 
The hypothesis that “3D tumor cell constructs in physiological environments most closely 
approximate in vivo growth” will be explored in this project. The hypothesis will be proven using 
the following specific aims: 
 
1. To show that 3D tumor constructs are able to approximate in vivo cell physiology. 
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2. To show that 3D tumor constructs grown in physiologically replicated environments are 
physiological surrogates of tumor xenograft SCID mice models. 
3. To use the 3D tumor constructs in replicated physiological environments for drug testing 
applications. 
 
This project will focus on the development of a 3D model for the characterization and treatment 
of osteosarcoma, the most common primary bone cancer. The project will be broken down into 5 
stages. 
 
Stage 1: Silk fibroin from Bombyx mori silkworms will be freeze dried to create a porous 3D 
scaffold with good mechanical properties. 
 
Stage 2: Osteosarcoma cells will then be seeded onto the scaffold. Molecular profiles will be 
obtained by carrying out RT-PCR for angiogenic growth factors and proliferative markers and 
these will be compared to those obtained from osteosarcoma cells injected into SCID mice or 
grown in a traditional 2D monolayer culture. Immunohistochemical staining for angiogenic and 
proliferative markers will also be carried out.  
 
Stage 3: Osteosarcoma cells will be co-cultured with human immortalized fibroblasts or 




Stage 4: The sensitivity of the 3D tumor models to existing chemotherapeutic drugs will be 
compared to 2D monolayer culture using traditional chemotherapeutics and anti-angiogenic 
agents. 
  
Stage 5: A bioreactor will be designed and fabricated. Seeded scaffolds will be cultured in the 
bioreactor and secretion profiles for index molecules will be obtained by carrying out real-time 
PCR. These will be compared to those obtained from osteosarcoma SCID mouse tumors or 
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1.1 Background and Significance 
Cancer can affect any part of the body and refers to a broad group of diseases in which cells 
divide and grow in an unregulated manner, resulting in malignant tumors that then invade 
adjacent parts of the body or spread to more distant areas through the lymphatic system or 
bloodstream. This process is referred to as metastasis, and is the major cause of cancer mortality. 
Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (13% of all 
deaths) in 2008 [1]. Thus, there is an urgent need to develop effective cancer therapeutics. This 
study will be focused on osteosarcoma, which is the most prevalent form of paediatric primary 
bone cancer and constitutes 20% of all primary bone malignancies [2]. 
 
Osteosarcoma is a malignant bone tumor that usually develops during the adolescent rapid 
growth period near the growth plates around the knee, arms, legs and pelvis, with the average 
age at diagnosis being 15 (Figure 1.1). It has an equal rate of occurrence in both sexes until the 
late teen years, during which it is more often seen in boys. A second peak in osteosarcoma is 
seen in people over the age of 60. Chemotherapy is often given in conjunction with surgical 
resection and drugs used include cisplatin, doxorubicin, ifosfamide, and high doses of 
methotrexate with leucovorin, although carboplatin, cyclophosphamide, epirubicin, and 
etoposide have been added in some protocols.  Osteosarcoma has an estimated 5-year survival 
rate of 65% due largely to the resistance of these tumors to chemotherapy and the subsequent 
development of pulmonary metastasis [3]. It is widely established that, given its propensity to 
happen in the pediatric population, it is largely driven by a genetic as opposed to an 




Figure 1.1 X-ray of the left distal femur of a patient with osteosarcoma. The MRI shows mixed sclerotic 
and lytic permeative areas characteristic of solid tumors. Gross analysis of these tumors yield specific 
features of its three-dimensional architecture that cannot possibly be replicated in two-dimensional culture, 
like focal area necrosis (arrowed) and vascular proliferation. Photos provided from archive of A/Prof 
Nathan SS. 
 
Angiogenesis is a critical step in the metastatic cascade. As metastasis is the leading cause of 
cancer fatality, it is drawing increasing attention from the scientific community. Metastasis 
involves the dissemination of malignant cells from the primary tumor to other parts of the body. 
Steps include angiogenesis of blood vessels towards the primary tumor, the breaking away of 
cancer cells from the initial tumor mass, penetration into the surrounding blood vessels and 
finally settling and growing in a distant site [4]. Thus, it is crucial to understand and curb 




However, little progress has been made as the current in vitro drug testing methods yield drug 
efficacy results that differ largely from the in vivo xenograft findings. This is due to the use of 
two-dimensional (2D) cell culture systems that lack the spatial architecture of three-dimensional 
(3D) microenvironments, which may result in physiological and chemical intratumoral 
aberration and, in turn, play a large role in cancer cell signaling and metastatic potential [6]. 2D 
monolayer culture uses isolated subpopulations that do not reflect the complex nature of the 
tumor community, resulting in the loss of tissue-specific architecture, mechanical and 
biochemical cues, and cell-cell communication under such simplified and highly biased 
conditions [7]. As such, 2D assays would be expected to neither be able to conclusively classify 
cancer cells according to their potential for invasion nor determine anticancer drug efficacy with 
regards to cancer cell invasion and metastasis [7-10]. 
 
Conversely, animal experiments offer only limited control over isolated aspects of cell signaling 
due to the complexity of living systems, and they are also much less amenable to large-scale 
molecular biology research, though they give a more accurate anatomical and perhaps 
physiological representation of tumor development [11]. Moreover, species-specific metabolism 
pathways and signaling mechanisms undermine the data obtained in chemosensitivity assays 
when using xenograft models to predict the effect of the drugs in the human body. Moreover, it 
is the host cells that produce the extracellular matrix (ECM) in xenograft and transgenic models, 
thus, the ECM would be of animal origin and not from the human tumor, raising serious 
implications and issues regarding the tumor-stromal cell interactions and cell signaling observed. 
It is also costly to carry out high-throughput drug testing on animal models and extensive use of 
animal testing also comes with ethical concerns [6, 12, 13]. Thus, a 3D in vitro tumor model 
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would combine the high throughput advantage of monolayer culture systems with the 
physiological mimicry of the animal models, aiding the development of high throughput 
anticancer drug screening. This lack of good preclinical models is a major bottleneck for 
anticancer drug discovery and implementation. To address these challenges, 3D culture systems 
are now increasingly applied in the study of tumorigenesis. These 3D in vitro models show great 
potential in recapitulating the physiology of living tissue without the added issues of cross-
species variations associated with animal models. A well-characterized in vitro 3D tumor co-
culture model with replicated physiological parameters could be used for understanding 
tumorigenesis under pathologically-relevant and well-defined culture conditions, as well as the 
high throughput screening of novel drugs. 
 
A successful in vitro tumor model would improve the outcomes of the early stages of the drug 
discovery process. Using a 3D in vitro tumor model would improve the yield and quality of high 
throughput cytotoxic drug screening, cell-based assays, and ex vivo drug testing during the drug 
discovery phase, aiding in the development of novel drugs for the treatment of cancer [14]. 3D 
culture systems would also decrease the use of laboratory animals, especially in the context of 
toxicity assays, by increasing the predictive power of cell-based drug and toxicity studies 
through the reproduction of the target tissue phenotype, making it possible to obtain reliable 
biomedical data in vitro [7]. The 3D tumor model would also aid in the study of mechanisms 
activated in the early stages of tumor development and these could potentially be exploited in the 




The growth phenotypic properties, cellular regulatory pathways, and biochemical mechanisms in 
osteosarcomas must be better understood to improve the prognosis and treatment of the disease. 
These mechanisms are greatly influenced by the supporting stroma and the interstitial fluid 
pressure (IFP). However, very little work is being done using cell culture techniques that take 
these factors into account, and initial drug testing on cells cultured in 2D results in the selection 
of drugs that are ineffective when the work is moved forward into animal testing. Thus, this 
project aims to develop novel cell culture techniques that would help streamline the drug 
development process by bridging the gap between in vitro and in vivo studies. 
 
Uniquely, sarcomas provide a platform for experimental therapeutics as about 30 to 50% of 
patients may not respond to conventional chemotherapeutic protocols and, thus, are potential 
candidates for drug trials. Patient acceptance to use these experimental drugs would be strongly 
bolstered if they knew that a physiologically biomimetic system showed efficacy that was 
significant. 
 
An in vitro drug testing model would also exclude the added issues of intratumoral drug delivery, 
due to the ability of such a model to replicate the in vivo properties of a solid tumor sans blood 
supply. In this regard, it is conventionally assumed that hypoxia, through an upregulation of HIF-
1α, results in an upregulaton of VEGF-A. Our laboratory, however, has shown that the interstitial 
hypertension results in a downregulation of both HIF-1α and VEGF-A, independent of the 
interrelationship between these two molecules, despite there being a state of hypoxia in a severe 
combined immunodeficiency (SCID) mouse xenograft model. Thus, this project proposes to 
replicate these physiological conditions in vitro by culturing the 3D scaffolds in a pressure-
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controlled perfusion bioreactor, replicating physiological conditions found from SCID mice in 
order to create a biomimetic 3D tumor model.  
 
1.2 Objectives 
This project aims to use a tissue engineering approach to develop an in vitro 3D tumor model for 
drug delivery studies. The creation of a 3D tumor model comprised of tumor cells seeded on an 
architecturally biomimetic scaffold and maintained in a microenvironment with replicated 
characteristics of a solid tumor may be able to recreate the physiological milieu of solid tumors, 
allowing for more reliable in vitro drug testing protocols. This project proposes to replicate 
physiological conditions in vitro by culturing the 3D scaffolds in a pressure-controlled perfusion 
bioreactor with pressure readings that have been established by the laboratory, in order to create 
a novel biomimetic 3D tumor model.  
 
This project will explore the hypothesis “that 3D tumor cell constructs in physiological 
environments most closely approximate in vivo growth and drug response.” 
 
This project will focus on the development of a 3D model for the characterization and treatment 
of osteosarcoma, the most common primary bone cancer. The hypothesis will be proven using 
the following specific aims: 
 
1. To culture 3D tumor constructs statically, in a perfusion bioreactor and in vivo. 
2. To show that constructs grown in physiologically replicated environments are able to 
approximate in vivo cell physiology 
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3. To use the 3D tumor constructs in replicated physiological environments for drug 
testing applications. 
 
1.3. Scope of Dissertation 
This thesis is composed of seven chapters and is organized as follows: 
 
Chapter 1 gives an introduction of the research background, objectives and scope of the 
dissertation. 
 
Chapter 2 is a literature review focusing largely on the role the tumor microenvironment plays 
in tumor biology. The functions of cancer-associated fibroblasts and endothelial cells are also 
elaborated upon, as well as the mechanisms involved in angiogenesis. The limitations of 
conventional monolayer cultures and the advantages of 3D culture in bridging the gap between in 
vitro and in vivo experiments are also touched upon. The effect of mechanical stimulation on cell 
physiology and the use of bioreactors in mimicking these forces are also discussed. 
 
Chapter 3 focuses on the fabrication and characterization of the 3D biomimetic tumor construct. 
The porosity of the 3D silk scaffold was quantified using a mercury porosimeter. Following the 
fabrication of the scaffold, osteosarcoma cells were seeded and the viability of the osteosarcoma 
cells was assessed using alamarBlue assay. Histology with hematoxylin and eosin (H&E) 
staining was carried out to assess the migration of the cells into the scaffold. Secretion profiles 
were obtained by carrying out quantitative real-time PCR for angiogenic growth factors. 
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Immunohistochemical staining for HIF-1α, VEGF-A, and VEGF-A receptors was also carried 
out. 
 
Chapter 4 presents the study on the effects of co-culture on osteosarcoma cell biology. 
Osteosarcoma cells were co-cultured with human immortalized fibroblasts or human umbilical 
vein endothelial cells and the secretion profiles were compared to those obtained in Chapter 3. 
Transwell® migration assays were conducted to investigate the physiological effects of 
upregulated angiogenic factors in endothelial cell migration. Monoclonal antibodies for VEGF-A 
and IL-8 were administered to study the effects of those markers on endothelial cell migration. 
 
Chapter 5 provides cell cycle analyses for osteosarcoma cell lines cultured in 2D monolayer and 
3D scaffolds. Real-time PCR for proliferation markers E2F1 and cyclin B1 as well as RhoA, a 
Rho GTPase, were also carried out. Finally, cytotoxicity testing using alamarBlue assay with 
commercial cell cycle specific (e.g. doxorubicin) and cell cycle non-specific (e.g. cisplatin) 
agents titrated to clinically relevant doses were conducted for osteosarcoma cells in monolayer 
culture and in the 3D scaffolds. 
 
Chapter 6 explores the use of a perfusion bioreactor for the culture of the 3D scaffolds. 
Osteosarcoma cells were seeded onto the 3D scaffold and cultured in the perfusion bioreactor 
under atmospheric and elevated pressure. Secretion profiles were obtained and compared to the 
scaffolds grown under static culture conditions to investigate the effect of IFP on gene 
expression. Immunohistochemical staining for the tumor constructs in the perfusion bioreactor 
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was compared to that for osteosarcoma cells injected subcutaneously or seeded onto 3D silk 
scaffolds and implanted in the SCID mice. 
 












































It is essential to understand tumor biology in order to construct a model that best mimics the in 
vivo tumor. Specifically, the tumor microenvironment and the effect of stromal cells on tumor 
biology will be elaborated on. Metastasis is a key process in tumor progression, thus, the role of 
angiogenesis in tumor progression will also be discussed, with focus placed on the growth 
factors involved and cell invasion assays currently available. The current 3D models in use will 
be introduced, followed by the factors that need to be taken into consideration in the design of a 
suitable 3D engineered scaffold. To further improve on the ability of the system to recreate the in 
vivo state, the effect of pressure on tumor biology will also be taken into account and a perfusion 
bioreactor will be designed for long-term culture. 
 
2.2 Tumor Microenvironment 
The tumor microenvironment plays a key role in tumor progression. Tumor aggressiveness is 
enhanced by altered cell-cell and cell-ECM interactions, the development of ischemic and, hence, 
hypoxic zones, and the signaling between cells in spatially distinct niches, such as that between 
cells in the outer proliferative regions and those in the interior of the tumor [15]. Although 
cancer cells acquire the capability to undergo limitless proliferation and survival through the 
activation of oncogenes, dysregulation of normal regulator genes, and the inactivation of tumor 
suppressor genes, the formation of a clinically relevant tumor requires support from the 
surrounding normal stroma, which is comprised of cancer-associated fibroblasts, blood and 
lymphatic vascular endothelial cells, leukocytes and bone marrow-derived cells [8, 16, 17]. The 
microenvironment provides the essential cues for the maintenance of the cancer cells and aid in 
the initiation of metastasis, and studies have increasingly shown the positive correlation between 
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angiogenesis, cancer-associated fibroblasts, and inflammatory infiltrating cells with poor 
prognosis, highlighting the clinical relevance of the tumor microenvironment on aggressive 
tumor progression. Ironically, these downstream aberrations are not specific to cancer causative 
influences and represent disordered perpetuation of normal cellular function. The reciprocal 
interactions between tumor cells and those in the tumor microenvironment are critical in the 
evolution towards metastasis through the induction of angiogenesis, the promotion of tumor 
growth and invasiveness, and increasing tumor drug resistance, and it should not be surprising 
that many cellular and molecular elements of the microenvironment are emerging as attractive 
targets for anti-cancer therapy [16, 18, 19]. The attraction or activation of non-tumoral cells 
modifies the microenvironment, and tumor cells can also deposit or modify the ECM (Figure 
2.1). Most of these stromal modifications begin early during tumor progression during the 
transition stage from premalignant to malignant lesions, and may even precede cancer formation, 





Figure 2.1 Heterotypic cellular interactions in the tumor microenvironment. a) Tumor cells orchestrate 
through direct release of factors or indirect induction of tissue hypoxia or the development of necrosis. b) 
Tumor microenvironmental events promote tumor progression through the stimulation of tumor growth 
and survival, and the facilitation of invasion and metastasis. Abbreviations: B - B lymphocyte; BMDC - 
bone marrow-derived cells; BV – blood vessel; CAF – cancer-associated fibroblast; EC – endothelial cell; 
ECM – extracellular matrix; EMT – epithelial-to-mesenchymal transition; Gr – granulocyte; LEC – 
lymphatic endothelial cell; LV – lymphatic vessel; Mo – monocyte; MSC – mesenchymal stem cell; PC – 
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pericyte; T – T-lymphocyte; TAM – tumor-associated monocyte/macrophage; TC – tumor cells. Taken 
from Lorusso et al., Histochemistry and Cell Biology, 2008 [16]. 
 
Multiple cell types interact directly in 3D microenvironments in vivo via heterotypic cell-cell 
junctions or paracrine-mediated signaling mechanisms. Interactions between cancer cells and 
their supporting stroma results in increased growth and invasiveness, and also contributes to the 
formation of drug-resistant phenotypes [6, 14, 20]. However, very little work is currently being 
done on using tumors grown in 3D co-culture systems for chemosensitivity studies. 
 
Cancer metastasis involves a dynamic interaction and remodeling of the microenvironment 
which is often facilitated by other cell types in the surrounding stroma [6]. The stromal cells 
induce the transcription programs that allow the mesenchymal phenotypes to invade distant 
tissues and establish a new environment [21]. The three-dimensional co-culture of cells could 
potentially induce cell-cell and cell-matrix interactions, affect the penetration of drugs, and 
control the accessibility and function of various adhesion molecules and growth factors. The 3D 
matrix establishes tissue-scale solute concentration gradients and local pericellular gradients by 
binding effector proteins, such as growth factors and enzymes [22]. These biological factors 
control cell growth, differentiation, and death, contributing to the formation of drug-resistant and 
highly invasive phenotypes [14]. More complex in vitro models of human tissues which involve 
co-culture with supporting stromal cells could also respond differently to mechanical forces as 




In order to study the effect of the supporting stroma on tumor biology, osteosarcoma cells will be 
co-cultured with human immortalized fibroblasts and human umbilical vascular endothelial cells 
(HUVECs), as these cells typically contribute the bulk of the tumor mass. 
 
2.2.1 Cancer-associated Fibroblasts 
Fibroblasts are the major constituent of the stroma and are responsible for the secretion of 
increased levels of ECM proteins, growth factors, and chemotactic factors to coordinate the 
migration of inflammatory cells and vascular progenitor cells in vivo, as well as supply the 
scaffold structure for cell growth and proliferation [17, 23, 24]. Fibroblasts also play a critical 
role in ECM remodeling through the secretion of matrix metalloproteinases (MMPs) that degrade 
the surrounding ECM [21]. Cancer-associated fibroblasts (CAFs) are functionally and 
phenotypically distinct from normal fibroblasts, perpetually activated, and do not undergo 
apoptosis [17]. CAFs are the main cellular component of the tumor stroma and provide an 
essential communication network through the secretion of growth factors and chemokines, 
thereby inducing an altered ECM and providing additional oncogenic signals which enhance the 
proliferation and invasion of cancer cells [18, 21]. CAFs secrete angiogenic and growth factors 
which include members of the vascular endothelial growth factor (VEGF) family and SDF-1α, as 
well as recruit inflammatory cells and endothelial progenitor cells [17, 18, 25]. 
 
Pleomorphism is a histological variability in neoplastic cell size and shape as a result of the 
acquisition of somatic mutations. However, the extensive pleomorphism in some malignancies, 
whereby few adjacent cells share similar morphology, is unlikely to be the result of mutations 
alone and the cells may have acquired the altered phenotype and pleomorphism by sipping 
17 
 
plasma membrane and cytoplasmic components from adjacent stromal cells [26]. Time-lapse 
microscopy of SaOS2 or U2OS cells co-cultured with human gingival fibroblasts that used the 
expression of membrane-bound alkaline phosphatase to distinguish the tumor cells in co-culture 
showed extensive exchange of membrane between the tumor cells and fibroblasts. Furthermore, 
SaOS2 cells were able to establish physical continuity of their plasma membrane and cytoplasm 
with the co-cultured fibroblasts through cell processes, allowing for the exchange of membrane 
and cytoplasmic markers [27]. Labeled cytoplasmic material was also found in a range of 
melanoma and ovarian carcinoma cell lines, indicating that the phenomenon may be very 
widespread among malignant cells. Hence, cellular sipping between tumor cells and their 
supporting stroma may contribute to phenotypic change and the generation of diverse tumor cell 
populations, leading to tumor progression. 
 
The co-culture of tumor cells with fibroblasts was hypothesized to result in the stimulation of 
angiogenesis, and thereby allow for the modeling of a more aggressive tumor phenotype. In this 
study, osteosarcoma cells were co-cultured with immortalized fibroblasts in both a 2D 
monolayer and as a 3D co-culture model, and studies were conducted on the effect of co-culture 
on the resulting angiogenic factor secretion profiles and Transwell® migration assays. The 
effects ascribed by either cell type in the co-culture model will be teased by labeling the 
osteosarcoma cells in a subset analysis. 
 
2.2.2 Endothelial Cells 
Tumor growth is often accompanied by neovascularization, and the complex network of tumor 
blood microvessels allows for the adequate supply of nutrients and oxygen as well as the 
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drainage of metabolites. The tumor vasculature is composed of abnormal, hierarchically 
disorganized vessels that differ from those of normal tissues in terms of organization, structure, 
and function [28]. Nevertheless, despite its disordered architecture, it offers just sufficient 
function in conjunction with the unchecked growth characteristics of the cancer cell to afford 
viable solid tumor growth. Microvascular endothelial cells are also present in tumor masses and 
participate in angiogenesis through the formation of new blood vessels. These cells are 
responsive to shear stress in vitro, and microvascular homeostasis is partly controlled by fluid 
flow [22]. 
 
Endothelial progenitor cells (EPCs) contribute to the repair of vascular damage in vivo. EPCs 
originate from the adult bone marrow and circulate in the peripheral blood, and can be isolated 
from adult peripheral and umbilical cord blood [29]. EPC-induced neovascularization is initiated 
by hypoxia and vascular endothelial growth factor (VEGF), and can stimulate vasculogenesis in 
tumors by recruiting EPC and hematopoietic progenitor cells [30]. EPCs express the 
glycoprotein CD34 or VEGF receptor 2 (VEGFR-2), and CD34+ EPCs are believed to originate 
from the CD34+ hematopoietic stem cell and display an almost indefinite proliferation potential 
[31-34]. Circulating EPCs include bone marrow-derived endothelial progenitor cells and mature 
circulating endothelial cells derived from the existing vasculature, the former able to target tumor 
vessels and participate in vasculogenesis [30, 31]. EPCs migrate through the bloodstream and 
extravasate through the endothelium towards the site of neovascularization. 
 
In contrast, HUVECs derived from vessel walls are widely considered to be differentiated, 
mature endothelial cells, although they can be passaged for at least 40 population doublings in 
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vitro and display similar growth kinetics to EPCs [35-38]. A study has found that the complete 
hierarchy of EPCs can be identified in HUVECs derived from vessel walls and discriminated 
using their clonogenic and proliferative potential [39]. Given these findings, this study will co-
culture HUVECs with osteosarcoma cells in order to mimic the metastatic niche, allowing for the 
study and potential targeting of metastatic tumors. 
 
2.3 The Role of Angiogenesis in Tumor Growth and Metastasis 
Tumors require a viable vascular supply in order to grow beyond the limits of oxygen and 
nutrient diffusion into tissues, and the theory that tumor growth is dependent on angiogenesis 
was proposed by Folkman in 1971, who had demonstrated then that solid tumors were 
completely dependent on angiogenesis for growth beyond a diameter of 2mm [16, 18, 40-42]. 
Furthermore, convective mass transfer from blood vessels would allow for increased perfusion, 
which would aid in the transport and replication of secondary cell types that may play critical 
roles in tumorigenesis, metastasis, and the efficacy of chemotherapy [43]. 
 
Angiogenesis is the formation of new blood vessels from the endothelium of the existing 
vasculature and is fundamental to tumor growth, progression, and metastasis [44, 45]. 
Angiogenesis is activated in tumors by increased levels of promoters of angiogenesis and 
decreased endogenous inhibitors [46]. Excessive tumor cell proliferation and the subsequent 
development of hypoxia lead to an overproduction of pro-angiogenic factors and the loss of 
inhibition of angiogenesis at the primary tumor site leads to the disintegration of the basement 
membrane [16]. A critical step in the process of tumor angiogenesis is the outgrowth of 
endothelial cells from preexisting capillary vessels and their migration towards the tumor cells 
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under the stimulation of angiogenic growth factors. Following which, proliferating endothelial 
cells remodel the ECM via MMPs and align into tube-like structures [47, 48]. This increase in 
proliferation and mobility of vascular endothelial cells due to the overexpression of angiogenic 
factors by the tumor cells is closely linked to invasion and metastasis, and the activation of 
angiogenesis by primary tumor cells at metastatic sites converts micrometastases to 
macrometastases (Figure 2.2). Circulating endothelial cells have been found to play a crucial role 
in sustaining angiogenesis in both the primary and metastatic tumors [30]. High levels of 






Figure 2.2 Schematic diagram illustrating the different stages in cancer metastasis whereby cancer cells 
spread from a primary tumor site to a distant site in the body to form the metastatic tumor. Taken from 
Lee et al., Trends in Biotechnology, 2007 [4]. 
 
Several factors with angiogenic properties have been identified over the past decades and focus 
will be placed on VEGF-A, interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) for 
this review, as well as the oxygen-sensitive transcriptional activator, hypoxia inducible factor-1α 




2.3.1 Vascular Endothelial Growth Factor 
The VEGF family is comprised of the five VEGF glycoproteins (VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and VEGF-E) and placental growth factor-1 (PlGF-1) and PlGF-2. VEGF-A has been 
identified as the key mediator of tumor-associated angiogenesis, thus, it is the most well-
characterized and is currently the key target in anti-angiogenic therapy [53, 54]. VEGF is 
secreted by both cancer and stromal cells and mediates the detachment of pericytes and the 
breakdown of the existing basement membrane of tumor-associated blood vessels by interacting 
with the angiopoietin/Tie signaling system, thereby increasing their permeability [55, 56]. VEGF, 
together with bFGF, angiopoietin 1 and angiopoietin 2, induces endothelial cell proliferation, 
migration and assembly into vascular networks [57]. VEGF is upregulated by HIF-1 and 
platelet-derived growth factor, and downregulated by angiostatin, endostatin and 
thrombospondin [58-60]. 
 
VEGF effects its influence through tyrosine kinase receptors (VEGFR). VEGFR-2 has been 
found to mediate the majority of VEGF-A signaling in the tumor microenvironment for the 
regulation of microvascular permeability and endothelial cell proliferation [61]. VEGF is also 
thought to directly promote survival, migration and invasion of tumor cells as VEGFR are 
expressed on certain tumor types, and inhibitors of these receptors or ligands has been shown to 
inhibit tumor growth in preclinical breast and colorectal cancer models [53, 62-64].  
 
The inhibition of tumor angiogenesis is a plausible and promising strategy for the treatment of 
cancer and is used in conjunction with conventional chemotherapy or radiotherapy [45]. Anti-
VEGF therapy is believed to increase the chemosensitivity and radiosensitivity of tumor cells by 
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transiently normalizing the tumor vasculature in order to improve the delivery of drugs and 
oxygen to the tumor cells. Agents such as antibodies and soluble receptor constructs have been 
developed to target the VEGF system and Avastin (bevacizumab) has emerged as the leading 
anti-angiogenic agent. It is a recombinant humanized monoclonal antibody to VEGF-A, and is 
the sole anti-angiogenic drug approved by both the FDA and the European Medicines Agency 
for use in conjunction with chemotherapy for the treatment of metastatic cancer. Preclinical 
studies showed that Avastin markedly inhibited the growth of human tumors, xenografts and 
metastases and doses as low as 0.3 mg/kg were able to neutralize all free circulating VEGF-A in 
clinical trials. [53, 65, 66]. However, no predictive biomarker for the efficacy of anti-VEGF 
therapy has been identified, and therapies have only shown modest clinical success despite the 
enormous potential of anti-VEGF treatment for the inhibition of cancer growth [67]. Our own 
laboratory has demonstrated in multiple models the counter-intuitive regulation of VEGF-A in a 
physiologically pressurized environment. Anti-angiogenic therapy targeting VEGF-A therefore 
is fraught with a number of variables not previously considered. Thus, this study hypothesizes 
that tumor cells are able to activate angiogenesis via VEGF-independent pathways, thereby 
circumventing anti-VEGF treatment. 
 
2.3.2 Interleukin-8 
Although VEGF has been most widely investigated for its role in tumor angiogenesis, several 
other growth factors also feature prominently in this process. Interleukin-8 (IL-8, otherwise 
known as CXCL8) was originally discovered as a powerful chemoattractant and activator of 
polymorphonuclear leukocytes, but was later found to be expressed in many cancerous cell types, 
affecting proliferation and migration of cancer cells, tumor angiogenesis and metastasis. 
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Although IL-8 is barely detectable in healthy tissues, increased levels of IL-8 are usually 
observed in the serum of cancer patients, with elevated concentrations of IL-8 typically found in 
high-grade peritumoral fluids rather than low-grade tumors and benign conditions, and recent 
molecular biology investigations show that the local IL-8 production is related to its malignant 
origin and tumor progression [68]. It has been hypothesized that tumor cells produce IL-8 as an 
autocrine growth factor, and studies have shown that highly metastatic solid tumors such as 
prostate, breast, melanoma and ovarian cancer constitutively express IL-8 [69-73].  
 
IL-8 binds to CXCR1 and CXCR2, which are members of the seven transmembrane G-protein-
coupled receptor (GPCR) family, although its main biological effects are more dependent on 
CXCR2, with CXCR2 antagonists resulting in anti-tumor effects and increased sensitivity to 
oxaliplatin therapy in preclinical colorectal cancer models [74, 75]. IL-8 and CXCR2 induce the 
activation of Akt and mitogen-activated protein kinase (MAPK) signaling cascade, both of which 
are upregulated in numerous cancers and modulate cell survival, angiogenesis and cell migration. 
Increased IL-8 expression also increases downstream nuclear factor-kB (NF-kB) activity, with 
the NF-kB pathway being a key survival mechanism in a variety of cancer types and an inhibitor 
of apoptosis [74, 76-79] 
 
Overexpression of IL-8 has been found to be associated with VEGF-independent, tumor-
associated angiogenesis, thus, IL-8 may be the key to elucidating cancer resistance against anti-
VEGF therapy, and combining the effects of anti-VEGF and anti-IL-8 therapies has great 
potential in future anti-angiogenic studies [73, 74, 80, 81]. Anti-IL-8 monoclonal antibody has 
been shown to inhibit tumor growth, angiogenesis and metastasis of human melanoma in vivo, as 
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well as tumor growth in orthotopic bladder cancer xenografts, through the downregulation of 
matrix metalloproteases and NF-kB [72, 82]. The inhibition of IL-8 expression with small 
interfering RNA has also been found to decrease the adhesion, migration and invasion functions 
and oxaliplatin resistance of KATO-III gastric cancer cells [83]. Furthermore, HUVECs and 
human dermal microvascular endothelial cells constitutively express CXCR1 and CXCR2 
mRNA and protein, and studies have shown that recombinant human IL-8 induces endothelial 
cell proliferation and capillary tube organization while neutralization of IL-8 inhibits IL-8-
mediated capillary tube organization. [84-86]. Thus, research into anti-IL-8 therapy is gaining 
attention as it would be able to target both the tumor cells and the surrounding tumor vasculature. 
More importantly, it is to be expected that any agent that effectively deprives a tumor of its blood 
supply should be an effective anti-tumor agent. While the gains from anti-VEGF-A therapy have 
been modest, an alternative anti-angiogenic initiative in solid cancer control should be pursued. 
 
2.3.3 Basic Fibroblast Growth Factor 
Basic fibroblast growth factor (bFGF, otherwise known as FGF2) is a heparin binding growth 
factor which stimulates proliferation in a wide variety of cells including endothelial, 
mesenchymal, and endothelial cells, and has potent angiogenic activity in vivo. bFGF increases 
the growth of vascular smooth muscle cells and upregulates IL-8 during angiogenesis, as well as 
activates fibroblasts in tumor progression [17, 87]. It has been shown to highly activate Erk1/2 
and enhance the motility of osteosarcoma cells, as well as inhibit osteogenesis in the human 
osteosarcoma cell, SaOS2. Supplementation with bFGF increased the chemoresistance of 
osteosarcoma cells to doxorubicin in vitro and the administration of a bFGF inhibitor together 




2.3.4 Hypoxia Inducible Factor-1α 
Hypoxia is a reduction in the normal level of tissue oxygen tension and occurs in ischemia 
secondary to acute and chronic vascular disease. Similar mechanisms are operative in a focal 
manner in solid cancers whereupon appositional growth of cancer cells is able to occlude 
intratumoral blood vessels. This results in focal areas of necrosis previously described as ‘central 
necrosis’, a colorful if inaccurate representation of the phenomenon. While tumors exhibit 
aberrant new blood vessels, these are more related to a state of disordered transluminal fluid 
equilibrium rather than poor blood flow. Nevertheless, cancer cells undergo selection under this 
hostile environment that allows them to survive and even proliferate. Cancer cells activate 
signaling pathways that regulate proliferation, angiogenesis and death during hypoxia, and these 
processes contribute to the malignant phenotype, leading to aggressive tumor behavior, which is 
related to poor prognosis and resistance to radiotherapy [52]. 
 
Cells respond to reduced oxygen levels through the upregulation of hypoxia-inducible 
transcription factor 1 (HIF-1). HIF-1 is one of the best characterized stimuli for the induction of 
the angiogenic response through VEGF-A and the result of genetic alterations that activate 
oncogenes and inactivate tumor suppressor genes [89]. It is a heterodimer that consists of the 
hypoxic response factor HIF-1α and the constitutively expressed aryl hydrocarbon receptor 
nuclear translocator (ARNT, otherwise known as HIF-1β). HIF-1 activity depends on the 
availability of the HIF-1α subunit, which is rapidly ubiquitinated and degraded by proteosomes 
under normoxic conditions but increases in number during hypoxia and through the activation of 
oncogenes and/or inactivation of tumor suppressor genes [90]. During hypoxia, HIF-1 binds to 
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hypoxia-response elements (HRE) in the nucleus, resulting in the activation of hypoxia-response 
genes such as VEGF, genes encoding for erythropoietin, glucose transporters and glycolytic 
enzymes, cell survival factors, cell surface receptors, extracellular matrix proteins and 
transcription factors [91-93]. 
 
A recent study has shown that HIF-1 can bind to importin  in U2OS and HeLa cells, while a 
separate study on myocardial endothelial cells demonstrated that importin  binds to HIF-1 and 
facilitates its nuclear transport [91, 94, 95]. The phosphatidylinositol 3-kinase (PI3K) and MAPK 
pathways are activated in hypoxia, and the PI3K/Akt pathway has been shown to increase levels 
of HIF-1α protein [96, 97]. Activation of the MAPK pathway leads to the downstream activation 
of Ras/Raf/MEK-1/ERK1-2, which has also been shown to stimulate HIF-1α transactivation-














Table 2.1 Summary of the effects of key angiogenic factors. 
 
 
In view of the important role of VEGF-A, IL-8, bFGF, and HIF-1α in promoting tumor-
associated angiogenesis, these angiogenic factors were chosen to characterize the in vitro tumor 
models used in this study.  
 
2.4 In Vitro Cell Invasion Assays 
The migration of malignant cells from their site of origin to different tissues and the 
establishment of metastases is the principal reason for death from solid cancer. However, due to 
the complexity of cancer cell invasion in vivo, which involves dynamic interactions with cells of 
the microenvironment such as angiogenic blood vessels, fibroblasts, and inflammatory cells, it is 
impossible to simultaneously replicate all of these interactions in vitro, although it is possible to 
construct assays that investigate individual aspects of the invasion process [99]. The urgent need 
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to develop assays for the quantitative and reproducible measurement of the invasive propensity 
of cancer cells in order to identify inhibitors of cancer invasion has driven the development of in 
vitro invasion assays. There are several tests available for determining the migratory response of 
endothelial cells to angiogenesis-inducing or -inhibiting factors, with the most frequently used 
ones being modified versions of the Boyden chamber, whereby endothelial cells are placed on 
the upper layer of a cell-permeable filter and allowed to migrate in response to a test factor 
placed in the medium below the filter [100]. Transwell® Permeable Supports are commercially 
available plastic inserts possessing a cell-permeable membrane and designed for multi-well 
plates. By placing the cells on one side of the membrane and a chemoattractant on the other, 
invasion is determined by counting the cells after removing the retained cells from the cells that 
have traversed the cell-permeable membrane towards the higher concentration of 
chemoattractant. The system allows for quick, reliable, quantitative testing, using concentration 
gradients that may potentially reflect in vivo conditions [38, 101]. However, the reductionist 
assays must better mimic the native tumor microenvironment for the data from the in vitro 
systems to truly represent the in vivo behavior. The incorporation of stromal fibroblasts and 
endothelial cells is a possible method of improving the system when used in the study of 
angiogenesis [99]. 
 
2.5 Limitations of Conventional 2D Monolayer Cultures 
Conventional 2D monolayer cultures surfaces such as micro-well plates, tissue culture flasks, 
and Petri dishes have long been the most popular in vitro model for cancer research as they are 
simple and convenient to set up, with good viability of cells in culture. Unfortunately, they are 
unable to replicate the 3D microenvironment of actual tissue due to their lack of stroma, whereas 
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nearly all tissue cells reside in an ECM of complex 3D fibrous meshwork that provides complex 
biochemical and physical signals. Moreover, each type of cell is embedded in a considerably 
different 3D microenvironment that is difficult to emulate in 2D culture due to the lack of 
structural architecture and finite material selections [102]. Cells must also go through dramatic 
adaptations on 2D substrates, thereby altering cell metabolism and reducing functionality [103-
105]. Hence, 2D monolayer culture is likely to misrepresent findings to some extent by forcing 
cells to adjust to an artificial flat, rigid surface. 
 
2.6 Advantages of 3D Tumor Models 
In designing cell culture systems, the ability to grow cells in three dimensions has been elusive 
until very recently. Spheroid and agarose fragment impregnation within various suspensory 
culture devices (or bioreactors) have been pursued, acknowledging that 2D growth may be 
limited in the corroborative information it may give to its real-world solid tumor analogue. The 
main advantage 3D cultures have over 2D monolayers is their well defined geometry, which 
allows for the direct correlation of structure to function for theoretical analyses. The biochemical 
cues of the ECM such as growth factors, nutrients, and oxygen tension, together with the 
physical cues including the matrix microstructure and interstitial flow, can be incorporated into 
the engineered 3D tumor model according to spatial and temporal arrangements that will best 
simulate the in vivo tumor microenvironment [22]. The 3D architecture allows for the 
maintenance of cells with different phenotypes such as proliferating, non-proliferating, and 
necrotic cells reflective of the nature of in vivo tumors due to mass transport limitations, which 
allows for much more realistic cell populations instead of the cellular homogeneity of 2D 




3D models also aid in the support of the co-culture of multiple cell types, allowing for the 
interaction between tumor and stromal cells for the study of the regulation of neoplastic 
development. 3D heterologous in vitro co-cultures involving tumor cell interaction with 
endothelial cells and fibroblasts, immunocompetent cells, and the ECM must be established in 
order to successfully investigate the pathobiology of human cancer. These co-cultures also share 
a close resemblance to micrometastases and initial avascular regions of tumors and may be able 
to have a more in vivo-like response to cancer therapies. Thus, 3D co-culture models can, in 
principle, reproducibly reflect the invasive behavior of human tumor cells, mimic the tumour-
stromal cell interactions, and allow for the systematic investigation of multiple unknown 
regulatory feedback mechanisms between the tumor and stromal cells in a well-defined 3D 
microenvironment [106, 107]. As a result of their advantages in realistically modeling the in vivo 
tissue, 3D models have gained tremendous popularity and are now regularly used by many areas 
in the biosciences and this has led in turn to great progress in 3D culture techniques. 
 
2.7 Current 3D Tumor Models 
Spontaneous aggregation, liquid overlay cultures, and spinner flasks were traditionally the most 
widely used techniques to produce multicellular tumor spheroids that functioned as 3D in vitro 
tumor models. As a result of more sophisticated tissue engineering methods available, these 
spheroids are now being replaced by engineered scaffolds, which provide a supporting 
framework for cell attachment and proliferation and results in tumor behavior that is more 




2.7.1 Multicellular Tumor Spheroids 
Multicellular spheroids are comprised of monoculture tumor cells or a co-culture of tumor and 
stromal cells organized in a 3D arrangement. They can be formed when tumor cell lines 
spontaneously aggregate to produce solid tumor cell spheroids that grow well in avascular 
conditions and mimic both the 3D organization and differentiated function of tissues to a much 
greater extent than 2D monolayers [8]. Unfortunately, such spheroids cannot be sustained 
beyond a critical size limit whereupon there is an initial core of necrotic tissue which forms a 
substrate at first but soon after disintegrates. 
 
In order to grow as 3D multicellular spheroids, the adhesive forces between the tumor cells must 
be greater than that for the substrate they are plated on, thus, spontaneous aggregation is often 
not possible. An alternative method is the widely used liquid overlay technique which prevents 
matrix deposition, allowing some tumor cell lines to undergo homotypic aggregation. Cells are 
grown over an agar base in media but do not adhere to the substratum. Agarose and reconstituted 
basement membrane such as Matrigel® can also be used [108], however, as cell adhesion 
behavior is altered due to cell contact with the substratum, the use of Matrigel®, which is of 
rodent origin, or agarose is not ideal  [107]. 
 
Spinner flasks also prevent adherence by inhibiting contact with the culture vessel wall. They are 
used for growing cells as a suspension culture in liquid medium via impeller mixing, and the 
fluid movement aids in the mass transport of nutrients to and wastes from the spheroids. The 
cells do not come into contact with any substrates and this method allows for the culture of large 
numbers of multicellular tumor spheroids due to the dynamic suspension. Thus spinner flasks are 
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the preferred method for growing spheroids, while static liquid overlay culture in 96-well plates 
are favored for monitoring individual spheroid growth and co-culture [8]. The design of the 
Rotary Cell Culture System is a tremendous improvement on the spinner flask, allowing for the 
formation of larger and more morphologically and functionally differentiated tumor spheroids 
[109-111] (Figure 2.3). 
 
 
Figure 2.3 Scanning electron microscopy images of 3D multicellular spheroids cell cultures (7 days of 
culture) of (a) HT-29, (b) HCT-116/E6, and (c) LoVo human colon adenocarcinoma cell lines. Taken 
from Roncoroni et al., Cancer Investigation, 2010 [112]. 
 
These multicellular tumor spheroids are very similar to avascular tumor nodules and 
microregions of solid tumors in terms of growth kinetics, with proliferating cells mostly found 
on or near the surface due to mass transport limitations. Hence, multicellular spheroids also able 
to successfully recreate the intervascular microregions of large tumors and micrometastases prior 
to vascularization and have been widely used as they provide a 3D model for the study of tumor 
cell proliferation, cell death, differentiation, and metabolism. The ability of malignant cells to 
undergo homotypic aggregation with each other or heterotypic aggregation with other cells is 
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critical during the early stages of cancer metastasis and 3D tumor spheroids have also been used 
in in vitro drug screening systems for mechanistic studies of drug penetration, binding, and 
action [113, 114]. A study using oligonucleotide microarray analysis performed on NA8 
melanoma cells cultured in standard 2D or as multicellular tumor spheroids showed that culture 
as multicellular tumor spheroids resulted in the significant upregulation of the expression of 
more than 100 transcripts previously shown to play a role in melanoma progression and 
metastatic process, including IL-8 and angiopoietin-like 4 [115]. 
 
However, 3D tumor spheroids are incapable of recreating distinct tumor niches as they lack a 
supporting framework for cell attachment and proliferation, thus, their utility beyond the 
prediction of micrometastatic behavior is questionable, and spheroids remain incapable in 
establishing the post-seeding phenomenon of environmental cell recruitment in propagating 
growth. 
 
2.7.2 Pre-fabricated Engineered Scaffolds 
Established strategies from tissue engineering such as the integration of biomaterials, scaffold 
fabrication, and micro/nano-fabrication techniques can be exploited to investigate the dynamic 
role of chemical, cell-cell, cell-ECM, and mechanical interactions in the pathogenesis of cancer 
[12, 13, 19, 116]. In recent years, biodegradable 3D engineered scaffolds commonly used in 
tissue engineering have been introduced as an improved method for mimicking the ECM and 
providing structural support to the seeded tumor cells [19]. These engineered scaffolds have 
great potential in recreating the natural environment of living tissue, and are able to promote the 
signaling pathways for cellular migration, proliferation and differentiation [117]. Hence, 
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engineered scaffolds consisting of natural molecules or synthetic polymers currently present one 
of the most promising experimental approaches for the development of a 3D tumor model [102, 
118-120] (Figure 2.4). The fabrication of a scaffold that is able to provide both mechanical and 
biochemical cues would allow for a biomimetic culture system able to simulate the natural in 
vivo conditions for the study of tumor growth and drug sensitivity. 
 
 
Figure 2.4 Aspects of tissue engineering that can be incorporated into cancer research [19]. 
 
As the natural ECM is a fully hydrated gel, bulk materials with more hydrophilic chemistry that 
are better at mimicking the aqueous in vivo environment are often preferred for use as the 3D 
matrix material [121-123]. Thus, hydrogel scaffolds such as collagen or other ECM proteins 
were the most commonly used prior to pre-fabricated scaffolds. 3D hydrogel scaffolds are able to 
produce more differentiated phenotypes as they provide both signaling and structural support to 
aid in spheroid organization and differentiation [124]. Examples of 3D tumor models that have 
been successfully constructed using collagen gels include models using colon, liver, and lung 
cancer cell lines [125-128], while ovarian and prostate cell lines have been cultured on 
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polyethylene glycol [129, 130] and polyhydroxoethylamethacrylate has been used for ovarian 
cell lines in another study [131]. Hydrogel-supported 3D in vitro human tumor culture systems 
have shown that tumors cultured in a 3D system respond to drugs in an in vivo-like manner, 
justifying the use of 3D culture systems in developing clinically-relevant drug screening for solid 
tumors [132]. The IC50 values of anticancer drugs have also been found to increase for cancer 
cell lines grown in the hydrogels compared to in 2D monolayers, more closely reflecting the 
results observed under in vivo testing [126, 127, 131]. However, poor cell adhesion due to the 
hydrophilicity of hydrogels, batch-to-batch variation, and the lack of cell binding motifs are 
common drawbacks for the use of hydrogels [122]. 
 
Engineered natural or synthetic scaffolds are three-dimensional cell culture matrices that were 
introduced to overcome the limitations of 2D culture. These scaffolds are able to support cell 
growth, organization, and differentiation within their structure and possess a broad range of 
architectural and material diversity as a result of the many methods already established due to the 
large range of tissues being modeled in tissue engineering. It is currently possible to control the 
physical appearance, porosity, permeability, mechanical characteristics, and nano-scale surface 
morphology of many of the scaffolds used in the field of regenerative medicine [120]. 
Biodegradeable, engineered scaffolds provide beneficial long-term growth and differentiation of 
a variety of cell types, including epithelial cells, neurons, endothelial cells, osteoblasts, 
chondrocytes, fibroblasts, and smooth muscle cells and currently represent one of the most 





A study using oral squamous cell carcinoma cultured on 3D gas-foamed poly(lactide-co-
glycolide) scaffolds has shown that the cells cultured on the 3D scaffolds have angiogenic 
growth factor profiles similar to those detected in vivo, while the angiogenic secretion profiles of 
these cells grown in 2D monolayer culture and 3D Matrigel culture differed from that in vivo 
specifically in IL-8 secretion. Similar results were obtained with MCF-7 breast cancer cells and 
U87 glioblastoma cells, and other groups have found similar results when culturing breast cancer 
cells on polymeric scaffolds [15, 137, 138]. The results suggest that cells grown within the 3D 
Matrigel system lack certain microenvironmental cues recreated within the 3D poly(lactide-co-
glycolide) engineered tumors [15]. 
 
A 3D Ewing sarcoma model grown on porous 3D electrospun poly(ε-caprolactone) scaffolds has 
been shown to closely mimic the morphology, growth kinetics, and protein expression profile of 
human tumors [139]. It was also found to have remarkable differences in the expression pattern 
of the insulin-like growth factor-1 receptor as compared to 2D monolayer culture and was more 
resistant to traditional cytotoxic drugs than cells in the 2D configuration. MCF-7 breast cancer 
cells grown in poly(lactic acid)/poly(vinyl alcohol) blend microspheres with or without chitosan 
were treated with doxorubicin, paclitaxel or tamoxifen and it was shown that the anti-
proliferative effect of the drugs in the 3D model was significantly lower than in 2D monolayer. 
There was also a 2-fold increase in collagen content by cells in the microspheres cells grown in 
2D, suggesting a greater synthesis of extracellular matrix in the 3D model that then acted as a 
barrier to drug diffusion. Thus, cellular architecture, phenotypic variations, and extracellular 




Despite the growing shift to 3D culture, existing in vitro testing methods using pre-fabricated 
scaffolds involve culturing only the tumor cell lines, despite the fact that in vivo cancer 
progression is supported by the active participation of both the tumor cells and the surrounding 
host stromal cells [141]. Moreover, it is critical that tumor cells be co-cultured with cell types 
present in the original tumor as cancerous tissues are of a complex heterogeneous nature, 
containing multiple subpopulations of cancer cells that differ in functional properties, and 
interactions between cell types can alter drug sensitivity [117, 142]. Co-culturing the 
osteosarcoma cells with the supporting stromal cells would recreate the cell-to-cell signaling 
present in tumors in vivo, thereby allowing for more accurate results from drug sensitivity testing. 
 
Advances in 3D cell culture techniques have made it possible to develop increasingly complex 
and differentiated in vitro co-culture tumor models, further aided by the recent availability of 
immortalized human stromal elements such as fibroblasts and endothelial cells, allowing for the 
recreation of more authentic, in vivo-like microenvironments [143]. The accurate control of 
variables including cell types, ECM components, and experiment duration, would result in 
realistic tissue-like structures which are better able to model the differentiated and dynamic 
microenvironments of human cancers than 2D monolayers, allowing for more in vivo-like 
responses to therapeutic agents. In order to develop a physiological microenvironment, different 
cell types must co-localize with cell-cell interactions and the exchange of growth factors and 
other biological effectors, manufacture an ECM for mechanical stability and the regulation of 
cell function, and synthesize interstitial fluid with necessary nutrients and biological effectors 
necessary for tissue differentiation and maturation. 3D in vitro co-culture models have the 
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potential to satisfy these requirements, so as to produce credible and reliable preclinical tumor 
models. [8] 
 
2.8 Engineering a 3D Tumor Model 
The 3D scaffold provides structural support and mechanical cues for cell adhesion, stimulates the 
formation of ECM, and allows for the generation of concentration gradients for oxygen, nutrients, 
and growth factors in the tumor microenvironment for the development of distinct local cell 
behavior and cellular heterogeneity within the tumors [19, 144]. The molecular interplay 
between all these factors is tightly regulated by spatiotemporal concentration profiles that arise 
as a result of pro-angiogenic factor production, diffusion, circulation, interstitial flow, 
consumption, and elimination. In order to successfully investigate the pathobiology of the 
disease, the engineered tumor model used should ideally replicate these relationships and 
reconstruct the characteristic 3D architecture of the native tissue, so as to provide biologically 
relevant culture conditions [12, 14]. 
 
As native tissue is made up of hierarchical structures, a multi-scale approach to scaffold 
fabrication is often required in order to best mimic the original tissue. It is now possible to 
control the scaffold down to the macro- and nano-scale due to the growing variety of techniques 
now available, making it possible to control the scaffold’s size and shape, pore size and 
geometry, porosity, pore interconnectivity, and surface topology. Besides its structure, the 
degradation rate and products of the scaffold much also be considered as controlled 
biodegradability is an essential requirement for 3D scaffolds that are meant to be implanted, with 
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the scaffolds usually designed to degrade at the rate that the in-growing tissue replaces them 
[102]. 
 
Poly(α-hydroxyacids) such as poly(glycolic acid), poly(lactic acid), and their copolymer 
poly(lactide-co-glycolide), are the most widely used synthetic polymeric materials in tissue 
engineering [145]. These polymers are well-characterized and have gained FDA approval for 
human use. Thus, poly(α-hydroxyacids) are very popular and have been fabricated into 3D 
scaffolds via a wide range of techniques [146, 147]. However, poly(α-hydroxyacids) tend to 
degrade by bulk erosion as opposed to surface erosion both in vitro and in vivo. This could lead 
to the simultaneous release of a large quantity of degradation products, which could result in the 
release of high concentrations of lactic and glycolic acid and cause the acidification of the 
culture medium. This is of concern as even non-toxic concentrations have been shown to lead to 
a decrease in cell proliferation, rapid cell differentiation, and mineralization failure [148]. For 
instance, in the case of poly(lactide-co-glycolide), the pH of the degradation solution could cause 
autocatalysis, with the lowered pH in the local environment leading to an increase in the 
degradation rate [149]. Thus, although poly(α-hydroxyacids) have been shown to possess good 
cellular and tissue biocompatibility, problems persist that limit their application as biodegradable 
polymers.  
 
To address the requirements for the tumor construct, the scaffold used should: 
1. Provide mechanical support to the seeded cells to aid in their interaction 
2. Possess suitable porosity that allows for medium perfusion and cell infiltration into the 
scaffold in vitro, as well as vascularization in vivo 
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3. Act as a substrate for ECM deposition 
4. Have good biocompatibility and not incite an active chronic inflammatory response 
5. Degrade in a controlled manner with non-toxic degradation products to facilitate in vivo 
tumor growth 
 
In order to achieve these goals, silk fibroin produced by Bombyx mori silk worms was chosen as 
the scaffold material for the 3D tumor model. 
 
2.8.1 Silk Fibroin as the Scaffold Material 
Silk fibroin is a valuable material in the textile industry. It is a natural polymer and has been 
widely used clinically as sutures due to its excellent mechanical strength and elasticity. It is 
comprised of fibroin, a filament core protein, and a glue-like coating of sericin proteins [150, 151] 
(Figure 2.5). It is composed of 45.9% glycine, 30.3% alanine, 12.1% serine, 5.3% tyrosine, 1.8% 
valine, and 4.7% of the other 15 amino acid types, thus, resembles the amino acid composition of 
ECM [150]. Silk fibroin exists in one of two phases: random coil as either α-helix structures (silk 
I) or more stable anti-parallel β-pleated sheets (silk II) held together by hydrogen bonds [152, 
153]. Silk fibroin in its α-helix phase is water soluble and can be converted to β-sheets when 
subjected to heating or methanol treatment, and it is in this phase that silk fibroins possess 




Figure 2.5 Diagrammatic cross-section of a silk fiber. 
 
Silk is biocompatible, permeable to oxygen and water, has slow degradability, good cell 
adhesion and growth characteristics, relatively low thrombogenicity, and good mechanical 
properties [157]. It can also be easily processed and surface modified for tissue engineering 
applications, thus, is a very suitable starting material for fabricating the scaffold [158]. However, 
despite its excellent mechanical properties, the use of silk fibroin as a scaffold material in tissue 
engineering is a fairly recent concept, likely due to the misconception that Bombyx mori silk 
triggers an inflammatory response in vivo [159-162]. This has been rectified by the removal of 
the sericin coating on the silk fibroins through a degumming process, often using alkali 
hydrolysis that involves the dispersion, solubilization, and hydrolysis of the sericin polypeptides 
[162-165]. 
 
Biodegradability is also often an essential factor, and the rate at which degradation occurs should 
ideally coincide as far as possible with the rate of tissue formation [166, 167]. Silk fibroin is a 
peptide polymer, thus, is susceptible to proteolytic degradation in vivo, at a rate slower than 
poly(α-hydroxyacids) which degrade by hydrolysis. The extensive hydrogen bonding in the anti-
parallel β-pleated sheets allow for enhanced environmental stability, allowing for long-term 
degradation so as to ensure that the tumor cells remain fully supported in vivo to allow for 
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accurate comparisons between the mouse and bioreactor models. In vivo studies have shown 
porous B. mori silk scaffolds to have a degradation rate of 2 to 6 months when prepared using an 
all-aqueous process degradation. The in vivo degradation was found to be mediated by 
macrophages, suggesting that silk is not only biodegradable but also bioresorbable [168, 169]. 
Osteoblast and osteoclast cells have the potential to erode silk films via the expression of 
metalloproteinases and integrin for in vitro systems [170]. Silk fibroin has been demonstrated to 
be comparable to collagen in terms of its ability to support cell attachment, as well as induce 
appropriate cell morphology and growth patterns due to its protein properties [171]. Culture on 
porous silk scaffolds has shown good cell metabolic activity and differentiation, with increased 
production of sulfated glycosaminoglycan and collagen I and II by cells of both epithelial and 
mesenchymal lineage, and its ability to facilitate good cell attachment despite little evidence of 
recognizable cell-adhesion motifs is likely mediated via the adsorption of serum proteins from 
the culture medium [172-174]. 
 
Porosity is essential for the fabrication of a successful scaffold and scaffolds must be porous with 
adequate pore size to facilitate cell infiltration and the diffusion of nutrients and waste products 
throughout the structure in order to achieve the goal of tissue reconstruction. Good porosity is 
also important to ensure that the scaffold is able to support cell migration, proliferation, and 
growth factor transport [166]. The obvious, if poorly understood, nature of 3D growth also 
imparts a spatial architecture and conformational change that in itself can cause cellular changes 
that have been mostly disregarded due to inadequate culture models. In order to fabricate porous 
silk fibroin scaffolds, a large range of methods have been used, examples include particulate 
leaching, gas foaming, freeze-drying, phase separation, and micromolding [175-179]. Freeze-
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drying was the chosen method of fabrication due to its efficient ability to generate high porosity 
scaffolds with interconnected pores [180]. 
 
Silk scaffolds have recently been used in demonstrating the increase in the invasive potential of 
breast adenocarcinoma MDA-MB-231 cells [181] and in the development of a model for prostate 
cancer metastasis to bone when coupled with BMP-2 [182], highlighting the suitability of silk 
scaffolds in the fabrication of biomimetic tumor constructs. A review of the current literature 
revealed that work on 3D models has been focused on epithelial carcinomas and as of yet there 
has not been work done on osteosarcoma models, thereby demonstrating the novelty of this study. 
 
2.9 Effect of 3D Culture on Cell Cycle Progression and 
Chemosensitivity 
Despite recent research focus on characterizing tumors grown in 3D, little work has been done 
on using these tumors for the cytotoxic evaluation of anticancer drugs. Tumor cells grown on 3D 
scaffolds have been found to increase collagen production, implicating an increase in ECM 
deposition [183]. Commercial cytotoxic and anti-angiogenic drugs will be tested on the 3D 
tumor constructs. Doxorubicin and cisplatin are commonly administered in chemotherapy for 
osteosarcoma patients and will be used for this study. In related studies, doxorubicin-treated 
osteosarcoma cells subjected to cytoprotection by the ECM have been found to maintain a potent 
repopulation capacity, indicating that the ECM contributes to failure in therapy of osteosarcoma 
in the clinical situation [14]. It has also been reported that the majority of cells grown in 
multicellular spheroids are in G1 phase rather than G2-M phase, as compared to 2D models [112, 
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184]. This slowly dividing and, hence, chemoresistant subpopulation in multicellular spheroids 
might also be protected from potentially lethal damage by cytotoxic agents [140]. 
 
There are numerous proteins and transcription factors that determine the fate of the cell. E2F 
proteins play critical roles in cell cycle progression, differentiation, and apoptosis, and have been 
attributed to cancer progression and chemoresistance [185, 186]. E2F proteins are situated 
downstream of growth factor signaling cascades and there are at least seven E2F proteins, of 
these, E2F1, E2F2, and E2F3 are transcriptional activators whereas E2F4, E2F5, E2F6, and 
E2F7 are repressors. The E2F family members that are transcriptional activators mainly interact 
with retinoblastoma protein (pRb), with much research focus having been placed on E2F1 [187]. 
E2F1 transcription activity is closely regulated in the cell cycle where it is under the control of 
pRb in G1, and pRb/E2F1-DP complexes have the ability to induce G1 arrest [188, 189]. The 
phosphorylation of pRb by cyclin-dependent kinases in late G1 leads to the dissociation of 
E2F1/DP heterodimers from pRb, thereby activating them. Activating members of the E2F 
family have been demonstrated to contribute to the oncogenic transformation of rodent 
embryonic fibroblasts and tumorigenesis when overexpressed [190]. 
 
The cellular reorganization events at the G2-M transition depend on the activation of various 
mitotic kinases, most importantly a protein complex (also known as the maturation-promoting 
factor) of cyclin-dependent kinase 1 (CDK1) and cyclin B1 [191]. Mitosis is triggered in all 
eukaryotic cells at the G2/M transition when the level of cyclin B1 rises past the threshold and 
activates the CDK1-cyclin B1 complex, and high CDK1-cyclin B1 activity promotes mitotic 
progression until all chromosomes are aligned at the metaphase plate of the mitotic spindle for 
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cell division [158]. Preliminary clinical data also suggests that chemotherapy resistance in non-
small cell lung cancer may be increased with decreased expression of cyclin B1 [192]. 
 
Cyclin-dependent kinase inhibitors (CKIs) play key roles in the regulation of the cell cycle and 
are implicated in the suppression of cell proliferation under stress conditions caused by a 
multitude of factors such as growth factor deficiency, DNA damage, heat shock, and exposure to 
heavy metals or anti-proliferative cytokines  [193]. CKIs are divided into the Ink4 and Cip/Kip 
families. The Ink4 family interacts with CDK4 and CDK6, while the Cip/Kip family inactivates 
cyclin-dependent kinase 2 (CDK2). The most studied member of the Cip/Kip family is 
p21
Waf1/Cip1
. It is a negative regulator of the cell cycle and has been identified as a p53-dependent 
protein involved in cell cycle checkpoints in the G1 and S phases through the inhibition of the 
activity of cyclin E-CDK2 and cyclin A-CDK2 complexes and the facilitation of kinase 
assembly with D-type cyclins [187, 193-196]. p21
Waf1/Cip1
 also causes cell cycle arrest in the G2 
and M phases, likely through transcriptional repression of Emi1, which is an inhibitor of the 
APC/C ubiquitin-ligase complex (Anaphase-Promoting Complex/Cyclosome) [193, 197-200]. 
The overexpression of p21
Waf1/Cip1
 has been shown to lead to cell cycle arrest and the appearance 
of senescence markers in many human cancer cell lines [201, 202], and studies demonstrating 
negative cell cycle regulation by p21
Waf1/Cip1
 as well as tumorigenesis in murine models with 
p21
Waf1/Cip1
 inactivation have led to the classification of p21
Waf1/Cip1





2.10 Interstitial Fluid Pressure 
Culturing cells in three-dimension subjects the cells to external mechanical inputs, and 
mechanical stresses regulate cell behaviour by influencing the spatial distribution of effector 
molecules in the pericellular environment, thus, mechanical and chemical signaling are coupled 
in tissues [22]. By changing the relative distances between cells, ECM components, and effector 
molecules, stretch and compression could directly alter extracellular gradients, cell-cell 
communication or local concentrations of secreted ligands. 
 
Tissue cells are continuously and cyclically exposed to hydrostatic pressure, shear stress, and 
compression and tension forces; and dynamically adapt by modifying their behaviour and 
remodelling their microenvironment [207, 208]. Mechanical force also regulates gene expression 
and results in altered cell behaviour by directly altering the DNA or by modulating the function 
of chromatin remodelling molecules [207]. According to the tensegrity model, integrins are 
linked to the nucleus through the cytoskeleton, and an applied force is transmitted to the DNA 
through the cytoskeleton, which then modulates gene expression by inducing conformational 
changes in chromatin.  
 
Slow interstitial flow is present in all vascularized tissues and is an important microcirculatory 
component between blood and lymphatic capillaries [22]. Moreover, elevated interstitial fluid 
pressure (IFP) is observed in most solid tumors [208]. Tumoral microvasulature formed through 
angiogenesis has been shown to be primitive and leaky. This causes an increase in oncotic 
pressure and, as a result, elevated IFP. The effect of IFP is especially significant in osteosarcoma 
as bone lacks a lymphatic system, thus, the excess interstitial fluid that forms within the tumors 
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accumulates within the interstitium and is not returned to the circulation via a lymphatic drainage 
system [209]. The co-supervisor, A/Prof Nathan, has reported observing higher IFP in 
osteosarcoma tumors than other soft tissue solid tumors. Moreover, different osteosarcoma cell 
lines have different susceptibility to pressure [210].  
 
Despite the prevalence of elevated IFP in tumors, the study of tumor biology and the 
development of chemotherapy are routinely done in in vitro culture systems at atmospheric 
pressure. However, this approach has been shown to be flawed in recent publications [210-212]. 
Bioreactors have been widely used in tissue engineering and are able to provide a fluidic 
environment for tissue engineered constructs to promote their viability and maturation [19]. Thus, 
this project proposes to replicate these physiological conditions in vitro by culturing the 3D 




One of the main hurdles in tissue engineering is the culture of large constructs due to mass 
transport limitations under static culture. Cells are unable to thrive beyond the 100 µm diffusion 
limit of oxygen and, hence, grow preferentially at the periphery of the scaffold. Bioreactors have 
been used to overcome this problem and can be classified into four main types: spinner flasks, 
rotary vessels, flow perfusion bioreactors and dynamic extension/compression bioreactors [213]. 
Each of these designs comes with their various advantages and limitations. Due to the need to 
mimic interstitial flow through the tumors and IFP values found in the SCID mice, the perfusion 
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bioreactor design was selected. Moreover, flow perfusion bioreactors result in improved cell 
distribution as compared to spinner flasks, rotary vessels, and static culture [214, 215]. 
 
 
Figure 2.6 Types of standard bioreactors [216]. 
 
Bioreactors have the added advantage of providing the technical means by which to perform 
controlled studies aimed at understanding specific biological effects related to tumor biology and 
metastasis [19]. The reproducible and controlled alteration of specific environmental factors 
would help reveal fundamental mechanisms of cell function in a 3D environment, thus, 
bioreactors originally developed for tissue engineering applications with the aim of replicating 
the in vivo environment ex vivo have the potential to further enhance 3D culture technology 
platforms in cancer research [217]. These bioreactors are often designed to provide biochemical 
and biomechanical cues reflective of the physiological environment in order to trigger tissue 




A bioreactor should ideally allow for the robust control of environmental factors such as pH, 
oxygen tension, temperature, nutrient transfer, and metabolite removal, as well as enable aseptic 
operation and the control of biochemical and physical regulatory signals which guide cell 
proliferation, differentiation, or tissue development [219]. Overcoming the diffusion limits of 
mass transport is especially crucial when modeling tumors due to their high vascularity, and 
oxygen levels have been found to play a role in ECM production and biosynthetic activity [219-
221]. Furthermore, fluid dynamic stress induced by culture medium flowing through the pores of 
the scaffold is believed to be the most important mechanical stimulus in activating mechano-
transduction signaling [222]. Thus, bioreactors offer the possibility of providing controlled tissue 




The formation of a clinically relevant tumor model requires a 3D structural support and cells of 
the surrounding stroma, of which cancer-associated fibroblasts and vascular endothelial cells are 
the most important. The 3D co-culture of tumor and stromal cells could induce cell-cell and cell-
matrix interactions, affect the penetration of drugs, and control growth factor gradients. Tumors 
are unable to grow beyond the limits of oxygen and nutrient diffusion into tissues without a 
viable vascular supply, and excessive tumor cell proliferation, together with the subsequent 
development of hypoxia, leads to the overproduction of pro-angiogenic factors and eventually 
angiogenesis at the primary tumor site. The inhibition of tumor angiogenesis is a recent 
therapeutic strategy for use in conjunction with conventional chemotherapy or radiotherapy, and 
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it is possible to construct assays that investigate individual aspects of the invasion process using 
modified versions of the Boyden chamber. It is acknowledged that conventional 2D monolayer 
cultures are unable to replicate the 3D microenvironment, as the 3D architecture allows for the 
maintenance of proliferating, non-proliferating, and necrotic cells reflective of the nature of in 
vivo tumors. Biodegradable 3D engineered scaffolds commonly used in tissue engineering have 
been introduced as an improved method for mimicking the ECM and providing structural 
support to the seeded tumor cells, and can be exploited to investigate the dynamic role of 
chemical, cell-cell, cell-ECM, and mechanical interactions in the pathogenesis of cancer. Slow 
interstitial flow is present in all vascularized tissues and is an important microcirculatory 
component, with elevated IFP having been observed in most solid tumors. The use of a 
bioreactor would make it possible to conduct controlled studies aimed at understanding specific 




















Chapter 3                          
Fabrication and Characterization of 












A well-characterized in vitro 3D tumor model with replicated physiological parameters could be 
used for the study of tumorigenesis under pathologically-relevant and well-defined culture 
conditions [7, 14]. The tumor microenvironment plays a key role in tumor progression and tumor 
aggressiveness is enhanced by 3D interactions between the cells and the ECM, the development 
of central hypoxia, and the signaling between cells in spatially distinct niches [15, 223, 224]. 
Biodegradable 3D engineered scaffolds have great potential in recreating the natural 
environment of living tissue and are able to promote the signaling pathways for cellular 
migration, proliferation, and differentiation, thus, currently present one of the most promising 
experimental approaches for the development of a 3D tumor model [19, 117]. It is hypothesized 
that 3D tumor constructs offer physiological environments that most closely approximate in vivo 
growth and are potential physiological surrogates of tumor xenograft SCID mice models. A 
biomimetic 3D tumor model could aid in the study of mechanisms activated in tumor 
development, and these mechanisms could potentially be exploited in the development of novel 
targeted chemotherapy. 
 
Several steps were taken in the construction of the 3D tumor model: 
1. The 3D scaffold was fabricated from degummed and dissolved Bombyx mori silk 
fibroins and characterized with scanning electron microscopy. 
2. 143.98.2 osteosarcoma cell line was seeded on the scaffold and cultured in vitro. 
3. The secretion profiles of the seeded cells were obtained and immunohistochemical 





The expression of angiogenic and proliferation markers for 143.98.2 cells grown on 2D tissue 
culture polystyrene, 2D silk cast films, 3D silk scaffolds, and frozen subcutaneous SCID mouse 
xenograft tumors will be compared to study the effect of the various culture conditions on gene 
expression. 
 
3.2 Materials and Methods 
3.2.1 Fabrication of the Porous Silk Scaffolds 
Silk fibroin from Bombyx mori silkworms was degummed using a solution consisting of 0.25% 
(w/v) sodium carbonate and 0.25% (w/v) sodium dodecyl sulfate at 98⁰C for an hour while 
stirring (PC-420D, Corning, NY, USA). This process was repeated once. The silk fibroin was 
rinsed in distilled water for an hour and dried overnight before dissolving in a ternary solvent 
consisting of calcium chloride, ethanol and distilled water in a molar ratio of 1:2:8 at 10% (w/v) 
concentration in a water bath maintained at 60-65⁰C. The solution was dialyzed overnight in 
distilled water and the concentration was calculated from its dry weight. The silk solution was 
diluted to 3% (w/v), placed in 55 mm diameter petri dishes, and freeze dried (Epsilon 1-4 LSC, 
Christ, Harz, Germany) overnight to form porous silk sponges. The sponges were then soaked in 
90% methanol to convert the silk into the β-sheet structure and washed with distilled water. Steps 





Figure 3.1 Steps in the fabrication of the porous silk sponge. (a) Raw Bombyx mori silk fibres were (b) 
degummed to obtain the silk fibroin. (c) The silk fibroin was dissolved in a ternary solvent and (d) 
dialyzed overnight. (e) The silk solution was diluted to 3% (w/v) and freeze-dried to obtain the porous 
silk sponge. 
 
3.2.2 Scaffold Characterization 
The scaffolds were vacuum coated with gold (JFC-1600, Jeol, Tokyo, Japan) and viewed under a 
scanning electron microscope (Quanta 200F, FEI, OR, USA) at 10 kV. Porosity was found using 
a mercury porosimeter (Autopore 9420, Micromeritics Instrument Corporation, GA, USA). 
 
3.2.3 Culture of 143.98.2 cells on Silk Scaffolds 
0.5 x 10
6
 143.98.2 osteosarcoma cells (ATCC, VA, USA) were suspended in Dulbecco’s 
modified Eagle’s medium (DMEM, Invitrogen, CA, USA) culture medium containing 10% fetal 
bovine serum (GIBCO) and 1% penicillin/streptomycin (PAN Biotech GmbH, Aidenbach, 
Germany). Three cell seeding methods were used: pipetting the cells on the surface, negative 
pressure permeation of the cells into the scaffold by aspiration with a syringe, and injection into 
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the centre of the scaffold using a 27G needle. The scaffolds were placed in 6-well plates 
containing 5 mL of culture medium and incubated at 37°C (Model 3111, Forma Scientific, OH, 
USA). Scaffolds were sliced and stained with 2 mL of culture medium containing 6 µL of 5 
mg/mL fluorescein diacetate (FDA, Molecular Probes, OR, USA) after 1 day of culture and 
viewed under the microscope (Olympus IX70, Tokyo, Japan). AlamarBlue assay (Invitrogen, CA, 
USA) was conducted on days 1, 5, and 7 to ensure the cells remained viable. 3 mL of DMEM 
solution containing 10 % (v/v) alamarBlue and 5% (v/v) fetal bovine serum was pipetted into 
each well of the 6-well plate and incubated for 3 hours. After incubation, 200 μL of the solution 
in each well was pipetted into a 96-well plate and transferred to a micro-titer plate reader 
(Sunrise, Tecan, Switzerland). Absorbance measurement was then taken at 570 nm and 600 nm 
and the percentage reduction was calculated using the following equation: 
 
3.2.4 Implantation of 143.98.2 cells in SCID Mice 
All animal experimentation proceeded after review and approval by the National University of 
Singapore Institutional Animal Care and Use Committee (NUS/IACUC approval, 077-07(A3)09). 
Female SCID mice (n = 6) were purchased at the age of 6 weeks from Jackson Laboratory 
(Maine, USA). Commercial 143.98.2 osteosarcoma cell line from ATCC was cultured for 2 days 
in medium and harvested by brief trypsinization. Cell viability was confirmed by trypan blue 
exclusion. The mice were weighed and anaesthetized with ketamine and xylene at 0.1 
ml/10grams administered intraperitoneally. The skin over the flank was scrubbed with 
chlorhexidine and 70% alcohol. 2 million 143.98.2 osteosarcoma cells were suspended in 0.2 mL 
saline and injected subcutaneously. The mice were observed and weighed weekly after 
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The scaffolds were fixed in 3.7% formaldehyde, embedded in paraffin and sectioned at 5 µm 
slices (RM2135, Leica, Germany). Hematoxylin staining was done according to standard 
protocols prior to viewing under the microscope. (Appendix A) 
 
3.2.6 Silk Cast Film Fabrication 
1 mL of 3% (w/v) silk solution was pipetted into each well of a 6-well culture plate and allowed 
to dry. The wells were then treated with 90% methanol and sterilized with ethylene oxide. 0.5 × 
10
6
 143.98.2 cells were seeded onto the plates and cultured as before to represent a 2D silk-based 
control. 
 
3.2.7 Analysis of mRNA Expression of Angiogenesis Markers 
To obtain the secretion profiles of the osteosarcoma cells, the cells were first disrupted from the 
scaffolds by adding 1 mL of TRIzol reagent (Invitrogen, CA, USA) to minced scaffolds in 2-mL 
centrifuge tubes. The tubes were vortexed and left to stand at room temperature for 5 min before 
being centrifuged at 13000 rpm for 15 min (Centrifuge 5810R, Eppendorf, Hamburg, Germany). 
The supernatant was transferred to a new tube and 200 µL of chloroform was added and left to 
stand for 5 min. The tubes were centrifuged at 13000 rpm for 15 min and the upper aqueous 
phase was transferred to a new tube. One volume of 70% (v/v) ethanol was added and the 
mixture was applied to an RNeasy mini spin column (Qiagen, CA, USA). RNA extraction was 
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done according to the manufacturer’s instructions. For cells grown in monolayer in tissue culture 
flasks, they were dislodged with HyQ trypsin (HyClone, MA, USA) and centrifuged prior to 
RNA extraction (Appendix B). For cells implanted in SCID mice (NUS/IACUC Approved, 077-
07(A3)09), a 30 mg sample of tissue was placed in a 2-mL microcentrifuge tube and 600 µL of 
Buffer RLT (Qiagen, CA, USA) was added prior to homogenization with a rotor-stator 
homogenizer (TH-220, OMNI International, GA, USA), The sample was then centrifuged at full 
speed for 3 min (Centrifuge 5810R, Eppendorf, Hamburg, Germany) before RNA extraction was 
performed on the supernatant (Appendix B). cDNA was synthesized from all the RNA samples 
using the  iScript cDNA synthesis kit according to the manufacturer’s instructions (Bio-Rad 
Laboratories, CA, USA). Real time-polymerase chain reaction (RT-PCR) was conducted using 
the iQ SYBR Green Supermix (Bio-Rad Laboratories, CA, USA) (Appendix C). N = 3 was used 
for each condition as it has been found to be sufficient for statistical analysis, and each 














Table 3.1 Table of angiogenic and proliferation primers 
Gene Name Forward Primer Backward Primer 
bFGF 5'-GGA GAA GAG CGA CCC TCA CAT 
CAA G-3' 
5'-CCA GTT CGT TTC AGT GCC ACA 
TAC CAA-3' 
Cyclin B1 5’-GCC TAT TTT GGT TGA TAC TGC-
3’ 
5’-ATC TGT CTG ATT TGG TGC TTA 
GT-3’ 
E2F1 5'-CAT CCA GCT CAT TGC CAA GAA 
G-3' 
5'-GAT CCC ACC TAC GGT CTC CTC 
A-3' 
GAPDH 5'-GAG TCA ACG GAT TTG GTC GT-3' 5'-CAT GGG TGG AAT CAT ATT GGA-
3' 
HIF-1α 5'-TCA CCA CAG GAC AGT ACA GGA 
TGC-3' 
5'-CCA GCA AAG TTA AAG CAT CAG 
GTT CC-3' 
IL-8 5'-CAC CGG AAG GAA CCA TCT CAC 
T-3' 
5'-TCA GCC CTC TTC AAA AAC TTC 
TCC-3' 
VEGF-A 5'-CTG CTG TCT TGG GTG CAT TGG-
3' 
5'-TCA CCG CCT CGG CTT GTC-3' 
 
3.2.8 Immunohistochemical Analysis 
Cultured scaffolds were fixed in 10% formalin before embedding in paraffin and sectioned as in 
Appendix A. Sectioned slides were deparaffinized in xylene and placed in 1% (v/v) Triton X 
(Bio-Rad) diluted in phosphate buffered saline (PBS) at 37⁰C for 1 h for antigen activation. 
Peroxidase block (Dako Cytomation, Glostrub, Denmark) was add to each sample and incubated 
at room temperature for 10 min. Protein block (Spring Bioscience, CA, USA) was added to 
slides to be stained for VEGF-A and incubated for 10 min. For angiogenic factor localization, 50 
µL of anti-HIF-1α mouse monoclonal IgG (Santa Cruz Biotechnology, CA, USA), anti-VEGF-
(A-20) rabbit polyclonal IgG (Santa Cruz Biotechnology, CA, USA), or mouse anti-VEGFR-2  
(AbD Serotec, Oxford, UK) 1⁰ antibody was used and incubated for 1h. Labeled polymer-HRP 
anti-mouse for anti-HIF-1 or labeled polymer-HRP anti-rabbit for anti-VEGF-A 2⁰ antibody 
(Dako Cytomation, Glostrub, Denmark) was added and incubated for 30 min. Slides were 
washed thrice with 1% (v/v) Tween 20 after each step. 50 µL of diaminobenzidine (DAB+) 
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substrate chromogen complex (Dako Cytomation, Glostrub, Denmark) was pipetted onto the 
sample and incubated for 5 min. Hematoxylin staining was performed on sections using standard 
protocols. Slides were dehydrated in an ethanol gradient, cleared in xylene and mounted for 
viewing under an Olympus IX71 microscope (Appendix A). For negative controls, the 1⁰ 
antibody was replaced with 50 uL of PBS. The images were then analyzed with Adobe 
Photoshop CS2 (Mountain View, CA) and the area for the pixels within the threshold set for the 
chromogen was divided by the total pixel area of the cells to obtain the percentage stained. 
 
3.2.9 Tumor Microenvironmental Readings 
After 7 days of culture, the percentage of dissolved oxygen and pH levels of the seeded porous 
silk scaffolds were analyzed. The surrounding culture medium was changed 1 day prior to 
analysis. For the dissolved oxygen readings, an oxygen probe attached to an ISO2 dissolved 
oxygen meter (World Precision Instruments, FL, USA) was used. A pH meter attached to the 
ML165 pH Amp (ADInstruments, NSW, Australia) was used for pH readings. The instruments 
were connected to the ADInstruments Powerlab ML880 (ADInstruments, NSW, Australia) for 
data logging. A scalpel was used to make an incision to the center of the scaffold for the 
insertion of the oxygen or pH probes. Dissolved oxygen and pH readings were taken from the 
center of the silk scaffolds and the surrounding culture medium. 
 
3.3 Results 
3.3.1 Characterization of Porous Silk Sponges 
The 3% (w/v) silk sponges fabricated had an average pore size of 270 ± 43 µm (ImageJ) and a 
uniform pore distribution. The average porosity of the scaffold was 78.8% (Autopore 9420, 
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Micromeritics Instrument Corporation). The silk scaffolds were cut into disc 5 mm in diameter 
and 5 mm in height using a biopsy punch for cell seeding (Figure 3.2). 
 
Figure 3.2 (a) SEM image showing the transverse section of a 3% (w/v) porous silk sponge (Quanta 200F, 
FEI). (b) Porous silk scaffold cut into 5-mm diameter discs using a biopsy punch. 
 
3.3.2 Optimization of Static Seeding Protocol 
FDA live cell staining showed that cells were poorly seeded and deposited mainly on the exterior 
of the scaffold for the pipetting and negative pressure permeation methods, suggesting that most 
of the cells failed to attach onto the scaffold and instead settled to the bottom of the 6-well plate. 
In contrast, cells were densely populating the interior of the scaffold when the injection method 
was used, and some cells had begun migrating outwards after 1 day (Figure 3.3). Thus, the 














Figure 3.3 FDA-stained microscopy images of the center 1-mm sections of scaffolds seeded with 
143.98.2 cells after 1 day of culture. Cells were seeded via pipetting (top), negative pressure permeation 




3.3.3 Osteosarcoma Cells Proliferate Well on the 3D Scaffolds 
0.5 × 10
6
 143.98.2 osteosarcoma cells were injected into silk scaffolds and cultured for 7 days. 
AlamarBlue® assay was conducted over the culture period on days 1, 5 and 7 and the percentage 
reduction calculated corresponds to the metabolic activity of the cells. The results show that the 
osteosarcoma cells survived well on the scaffolds over the culture period, with the metabolic 
activity increasing to a peak at day 5 before decreasing slightly by day 7  (Figure 3.4). 
 
 
Figure 3.4 AlamarBlue® assay for 143.98.2 cells cultured on 3% (w/v) silk scaffolds for 7 days. 
  
The 143.98.2 cells were found to transition from a cubiodal epithelial-like cell morphology when 
cultured on 2D T-75 flasks to a spindle shape morphology on the silk scaffold, reflective of the 
cell morphology in vivo (Figure 3.5a). This spindle shape morphology is characteristic of 
neoplasms of mesenchymal derivation, such as osteosarcoma. FDA live cell staining conducted 1 





























Figure 3.5 (a) Phase contrast microscopy image of 143.98.2 cultured on 2D T-75 flask. Scale bar = 100 
µm. (Olympus IX70) (b) Fluorescein diacetate live cell staining for 143.98.2 osteosarcoma cells seeded 
on a silk scaffold after 1 day. Scale bar = 200 µm. 
 
3.3.4 Detection of Angiogenic Markers with Immunohistochemistry 
Immunohistochemical staining was done for 143.98.2 cells grown on 3D silk scaffolds (Figure 
3.6) and SCID mouse subcutanoues tumors (Figure 3.7). Percentage stained for HIF-1α, VEGF-
A, and VEGFR-2 were 52.3%, 33.7%, and 31.6% for subcutaneous tumors and 45.9%, 34.8%, 
and 32.2% for the silk scaffolds respectively. The downregulation of HIF-1α synthesis in the 
interior of the subcutaneous tumors was not observed for the 3D silk scaffolds, which had 
uniform HIF-1α staining. This paradoxical downregulation in the production of HIF-1α despite 
the hypoxic conditions in the interior of the subcutaneous tumors was likely due to an increase in 
interstitial fluid pressure which was highest in the center of the tumor in the SCID mouse model, 
as shown in a previous evaluation done by the laboratory [212]. The high pressure in the center 
of tumors derives from a primitive vasculature that results in protein leak and increased oncotic 








Figure 3.6 Immunohistochemical staining for HIF-1α (left), VEGF-A (center), and VEGFR-2 (right) for 
3D porous silk scaffolds. Scale bar = 500 µm. Percentage stained for HIF-1α, VEGF-A, and VEGFR-2 
were 12.2%, 47.0%, and 41.6% respectively 
 
 
Figure 3.7 Immunohistochemical staining for HIF-1α (left), VEGF-A (center), and VEGFR-2 (right) for 
SCID mouse subcutaneous tumors. Scale bar = 500 µm. Percentage stained for HIF-1α, VEGF-A, and 







Table 3.2 Summary of percentage of 143.98.2 cells stained for the 2D culture, 3D silk scaffold, and SCID 
mouse subcutaneous tumor conditions. 
 HIF-1 VEGF-A VEGFR-2 
3D silk scaffold 45.9% 34.8% 32.2% 
SCID mouse subcutaneous tumors 52.3% 33.7% 31.6% 
 
3.3.5 Effect of Culture Conditions on Proliferation Marker Expression 
The expression levels of proliferation markers cyclin B1 and E2F1 for the different culture 
conditions was analyzed using real-time quantitative PCR. Standard descriptive statistics were 
used: mean and standard deviation were determined with respect to the GAPDH control. 
Analysis of the expression of cyclin B1 and E2F1 showed that their levels were similar for the 
2D tissue culture polystyrene and 2D silk cast films, indicating that the silk material does not 
play a large role in the proliferation rate of the seeded cells. In contrast, there was a drop in the 
level of cyclin B1 and E2F1 when the cells were grown in the 3D silk scaffolds, and this was 
much closer to the profiles observed for the subcutaneous tumors than when standard 2D tissue 





Figure 3.8 Effect of culture conditions on proliferation marker expression by 143.98.2 cells grown on 2D 
tissue culture polystyrene (TCPS), 2D cast film, 3D silk scaffold, and as subcutaneous SCID mouse 
tumors (n = 3). Expression profiles were normalized to the housekeeping gene GAPDH (iQ5, Bio-Rad). 
 
3.3.6 Effect of Culture Conditions on Angiogenic Factor Expression 
The expression of angiogenic factors such as HIF-1α, VEGF-A, bFGF, and IL-8 were 
investigated using real-time quantitative PCR (Figure 3.9). A paired t-test was used to compare 
data sets. Statistical significance was accepted at p < 0.05. Expression profiles for 2D and 2D 
cast film conditions were similar (bFGF p = 0.2, HIF-1α p = 0.8, IL-8 p = 0.005, VEGF-A p = 
0.03), thus, the silk surface did not significantly alter the expression levels of bFGF and HIF-1α, 
and only led to a slight upregulation of IL-8 and VEGF-A, while the overall trends in the 
expression of the genes remained the same. The secretion profiles for 2D culture differed 
significantly from angiogenic factor expression by cells grown on the 3D silk scaffolds (bFGF p 
= 0.006, HIF-1α p = 0.09, IL-8 p  0.0001, VEGF-A p = 0.04). Thus, the expression of 
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angiogenic factors is largely dependent on the architecture in which the cells are grown in. 
Moreover, the expression of HIF-1α and VEGF-A by 143.98.2 cells grown on the 3D silk 
scaffolds was elevated, suggesting that an increase in the expression of HIF-1α led to a 
downstream increase in expression of VEGF-A. There was also a very significant upregulation 
of IL-8 by cells grown in the 3D scaffolds as compared to 2D monolayer culture. The angiogenic 
expression profiles of the cells grown in the 3D silk scaffolds closely reflected that of the SCID 
mouse xenograft subcutaneous tumors in 2 out of 4 genes in the angiogenic panel. (bFGF p = 0.9, 
HIF-1α p = 0.3, IL-8 p  0.0001, VEGF-A p = 0.01) (Figure 3.10). The mean pO2 in the 3D 
tumor models and SCID mouse subcutaneous tumors were 5.6% and 0.22% respectively (p  
0.0001). These hypoxic zones within the center of the scaffolds could be responsible for the 
hypoxic drive within the 3D scaffold construct. 
 
Figure 3.9 Effect of culture conditions on angiogenic marker expression by 143.98.2 cells. Expression 
profiles were normalized to the housekeeping gene GAPDH (iQ5, Bio-Rad). Of note, 2D growth whether 
on polystyrene culture flasks or silk cast film was the same whereas 3D growth resulted in a strong 






Figure 3.10 Effect of culture conditions on angiogenic factor expression by 143.98.2 cells grown in 3D 
porous silk scaffolds and as SCID mouse xenograft subcutaneous tumors. Expression profiles were 
normalized to the housekeeping gene GAPDH (iQ5, Bio-Rad). *Statistically different at p < 0.05. ** 
Statistically similar at  p > 0.05. 
 
3.3.7 Dissolved Oxygen and pH Readings 
Oxygen and pH probes were used to measure the percentage of dissolved oxygen and pH inside 
the porous silk scaffolds and in the surrounding culture medium. The dissolved oxygen 
percentage was 5.58 ± 0.60% inside the seeded silk scaffolds and 8.54 ± 0.49% in the 
surrounding medium, reflecting the hypoxic condition in the center of the scaffold observed in 
the immunohistochemical staining for HIF-1α (p  0.0001). The pH in the center of the scaffold 













The change in cell morphology demonstrates the importance of the 3D architecture in which the 
cells are cultured. This can affect cell signaling cascades and, possibly, the malignant potential of 
the tumor cells (Figure 3.5). VEGF-A, bFGF, and IL-8 expression are modulated during 
angiogenesis. The signaling of these factors is regulated by cell-ECM interactions and 3D culture 
conditions, as can be seen from the expression profiles obtained (Figures 3.9 & 3.10). Hence, the 
expression of angiogenic factors is modulated by the 3D architecture in various 
microenvironments. Moreover, this 3D architecture allowed for the development of hypoxia 
within the scaffolds at levels close to that in the in vivo subcutaneous tumors, resulting in similar 
expression levels of HIF-1α (p > 0.05) by the cells grown in the 3D silk scaffolds and 
subcutaneous tumors. 
 
A study by Fischbach et al. also found the upregulation of VEGF-A and IL-8 when oral 
squamous cell carcinoma were cultured on porous poly(lactide-co-glycolide) scaffolds. As 
VEGF-A, bFGF, and IL-8 are also regulated through hypoxia [52, 70, 226], Fischbach et al. 
investigated if the enhanced secretion in 3D scaffold culture was due exclusively to the 
decreased pO2 within the 3D constructs. They found that the exposure of monolayer cultures to 0 
and 2% O2 led to an increase in VEGF-A and bFGF secretion similar in scale to when the cells 
were grown in 3D culture, while this oxygen deprivation increased IL-8 secretion only modestly, 
thereby suggesting that other aspects of the microenvironment inherent to the scaffold model, but 
not present in 2D cell culture, are crucial in IL-8 expression [15]. It is interesting to note that 
they found that cells situated within the 3D scaffolds had VEGF-A and IL-8 profiles very similar 
to the in vivo profiles, while the results in Figure 3.10 show that IL-8 levels for the SCID mouse 
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model were much lower. The tumors used for this part of the initial evaluation were historical 
archival tissue and their results were evaluated prospectively against freshly procured specimens 
in the later chapters of this thesis. The similar upregulation of angiogenic markers in the study by 
Fischbach et al. using oral squamous cell carcinoma and the results in this section suggests that 
this increased angiogenic potential is seen in multiple cell lines and not just limited to the 
osteosarcoma cell line used here. 
 
The results indicate that the 2D angiogenic secretion profiles differ significantly from that of 
subcutaneous tumors, while the angiogenic expression by cells grown on the 3D silk scaffolds 
more closely reflected that of SCID mouse xenograft subcutaneous tumors, justifying the use of 
this scaffold for the 3D model. Also, the expression levels of the proliferation markers was only 
slightly affected by the silk material, while 3D culture led to a significant downregulation. Cyclin 
B1 and E2F1 play important roles in cell cycle progression and a downregulation of these genes 
would suggest decreased proliferation rates. With the establishment of this basic model, its 
complexity can now be increased by the incorporation of supporting stromal cells during culture. 
For this purpose, the osteosarcoma cells could be co-cultured with stromal cells such as 
immortalized fibroblasts and human umbilical vascular endothelial cells. 
 
3.5 Conclusions 
In this study, it was shown that secretion profiles of 143.98.2 cells grown in 2D differed greatly 
from the same cells in SCID mouse xenograft subcutaneous tumors, thereby highlighting the 
inability of 2D culture systems to adequately represent in vivo cell physiology. Moreover, when 
the 143.98.2 cells were grown on the 3D silk scaffolds, they were able to express HIF-1α and 
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bFGF at levels much closer to that of the SCID mouse xenograft subcutaneous tumors. Thus, 
porous silk scaffolds are suitable for use in designing tumor constructs capable of approximating 





























Chapter 4                
Characterization of Tumor-Stroma 











In vitro tumor cell culture systems have been widely used as preclinical models for drug testing. 
Although 3D models are gradually being introduced to the field, very few have been able to 
mimic the heterogeneous tumor-stroma interaction of the tumor microenvironment. The 
interactions between tumor cells and their supporting stroma increases cancer aggressiveness 
through several mechanisms, with the induction of angiogenesis being the most important [16]. It 
is hypothesized that 3D tumor co-culture models offer a microenvironment that more closely 
resembles the physiological tumor microenvironment, while upregulated angiogenic factors 
stimulate endothelial cell migration. 
 
To prove that the effect of 3D architecture on angiogenic factor expression was not limited to 
just one osteosarcoma cell line, the real-time PCR experiments in Chapter 3 were repeated using 
the U2OS osteosarcoma cell line. The effect of tumor-stroma interaction on the angiogenic factor 
secretion profiles of U2OS cells was then investigated by co-culturing the tumor cells with 
immortalized fibroblasts or HUVECs. Transwell® migration assays were also conducted for 
U2OS cells grown in 2D and 3D monoculture or fibroblast co-culture systems to investigate the 
physiological effect of upregulated angiogenic factors on endothelial cell migration. Anti-IL-8 
and anti-VEGF-A therapy were also tested out on these models to investigate the role of 3D 







4.2 Materials and Methods 
4.2.1 Culture of Immortalized Fibroblasts 
Human bone marrow fibroblasts transformed with HPV-16 E6/E7 (CRL-11882, ATCC, VA, 
USA) were cultured in DMEM (ATCC, VA, USA) containing 10% fetal bovine serum and 1% 
penicillin/streptomycin. The medium was changed every 2 days. The cells were trypsinized and 
co-cultured with U2OS osteosarcoma cells (ATCC, VA, USA) when confluent. 
 
4.2.2 Culture of HUVECs 
Single-donor HUVECs (C2517A, Lonza, Switzerland) were thawed and cultured directly 
without centrifugation in EGM-2 (Lonza, Switzerland). The medium was changed the following 
day and every 2 days thereafter. The HUVECs were provided by A/Prof. Raghunath from the 
NUSTEP Tissue Modulation Laboratory. 
 
4.2.3 Transfection of U2OS Cells with GFP 
U2OS cells were tagged with green fluorescent protein (GFP) for cell sorting. U2OS cells plated 
at a density of 2 104 U2OS cells per well of a 6 well plate and cultured for 18 h in complete 
McCoy's 5A modified medium (Sigma-Aldrich, MO, USA). 2 mL of Moloney murine leukemia 
viral supernatant with the Retro-GFP vector (Retro-Easy Gene Expression System, Applied 
Biological Materials, BC, Canada) and 20 µL of 0.8 mg/mL polybrene (Sigma-Aldrich, MO, 
USA) were added to each well for 9 h. The wells were washed with PBS before a second hit was 
applied and left in the incubator overnight. The medium was replaced with fresh complete 
McCoy's 5A modified medium (Sigma-Aldrich, MO, USA) the following day and the cells 
allowed to culture to confluence. The medium was then replaced with culture medium containing 
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0.5 µg/mL puromycin (Applied Biological Materials, BC, Canada), which was used as a 
selection marker, and passaged upon confluence. The cells were sorted using a FACSVantage SE 
flow cytometer (Becton Dickinson, NJ, USA), and those found positive for GFP were collected 
and expanded in culture. 
 
 
Figure 4.1 Retroviral vector. 
 
4.2.4 Co-culture of U2OS Cells with Supporting Stromal Cells 
U2OS cells were co-cultured with immobilized fibroblasts or HUVECs under either 2D or 3D 
culture conditions. In the standardized 2D baseline, 2 104 U2OS cells were seeded on a T-75 
polystyrene flask and left to grow for 2 days to form cell clusters. 2 105 stromal cells 
(immortalized fibroblasts or HUVECs) were then added to the T-75 flask containing the U2OS 
cell clusters and cultured in McCoy's 5A modified medium (Sigma-Aldrich, MO, USA) until 
they reached confluence. These cells were either treated with TRIzol reagent (Invitrogen, CA, 
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USA) for RNA extraction or trypsinized and seeded in the 3D silk scaffolds at a cell density of 
0.5 106 cells per scaffold, and cultured for 7 days. U2OS cells transfected with GFP were used 
for the real-time PCR involving sorted U2OS cells cultured in 2D monolayers with the respective 
stromal cells. 
 
4.2.5 Fluorescence-activated Cell Sorting of Co-cultured U2OS-GFP Cells 
For the experiments involving transfected U2OS cells co-cultured with fibroblasts or HUVECs 
in 2D monolayers, the cells first underwent fluorescence-activated cell sorting (FACS) using a 
FACSVantage SE flow cytometer (Becton Dickinson, NJ, USA), and those found positive for 
GFP were collected for RNA extraction, which was conducted as in Section 3.2.7. 
 
4.2.6 DNA Quantification 
For DNA quantification using PicoGreen, the seeded scaffolds were rinsed with ice-cold PBS 
before being placed in cryovials and stored in liquid nitrogen. The scaffolds were then freeze-
dried and disintegrated. Homogenization was performed with 400µL of lysis buffer (Qiagen, CA, 
USA). The tubes were agitated for 5 mins and centrifuged at 16,000rpm for 5 mins. 20µL of the 
supernatant was added to 80µL of 200X-diluted PicoGreen in each well of a black 96-well plate. 
Fluorescence intensity was measured at 520 nm. 
 
4.2.7 Transwell® Migration Assays 
The migration assays were conducted as in Figure 4.2. For the 2D monolayers, 0.5 106 U2OS 
cells or U2OS co-cultured with immortalized fibroblasts as in Section 4.2.4 were plated directly 
on the bottom chamber of a 6-well Transwell® plate with pore size 8 µm (Corning, NY, USA). 
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For the 3D tumor constructs, 0.5 106 U2OS cells or U2OS co-cultured with immortalized 
fibroblasts were seeded in the silk scaffold, cultured for 7 days, and transferred to the lower 
chamber. For the control, 5.5 mL of complete McCoy's 5A modified medium (Sigma-Aldrich, 
MO, USA) was added to each well of the lower chamber, such that the medium was just able to 
touch the upper chamber. For the treated conditions, 1 µg/mL of anti-IL-8 monoclonal antibody 
(MAB208, R&D Systems, MN, USA) or anti-VEGF-A monoclonal antibody (Avastin, 
Genentech, CA, USA) was added to the culture medium in the lower chamber. The cells were 
placed in the lower chamber for 24 h. One-third of a T-75 flask of HUVECs pre-starved for 3 h 
in serum-free DMEM (Invitrogen, CA, USA) was plated onto each insert of the upper chamber 
and incubated for 6 h. The inserts were then removed and the unmigrated HUVECs on the top 
surface of the inserts were wiped off using sterile cotton buds soaked in PBS. The membranes 
were cut out and fixed in formalin overnight. For imaging, the membranes were soaked in 2 
µg/mL DAPI stain for 10 minutes and viewed under a fluorescence microscope (Olympus IX71 





Figure 4.2 Diagrammatic setup for Transwell® migration assays involving 2D and 3D tumor models. 
HUVECs (red) were plated in the upper chamber and allowed to migrate chemotactically towards the 
cells cultured in 2D monolayer (top) or 3D scaffold (bottom) in the lower chamber. 
 
4.3 Results 
4.3.1 No increase in DNA Content over the First 7 Days of Culture 
PicoGreen DNA quantification was conducted over the culture period on days 1, 3, 5 and 7. The 
total DNA concentration in the 3D scaffolds remained constant at around 10 µg/mL throughout 
the 7 days of culture, and this corresponds to approximately 0.5 106 U2OS cells as calculated 
from the standard curve. Thus, 0.5 106 U2OS cells were plated in monolayer on the lower 






Figure 4.3 DNA concentration within the scaffolds remained constant over the first 7 days of culture. 
 
4.3.2 Upregulation of Angiogenic Factor Expression by U2OS Cells in 3D 
Culture 
The expression of angiogenic factors bFGF, HIF-1, IL-8, and VEGF-A were investigated by 
conducting real-time quantitative PCR on Day 7. The expression profiles were normalized to the 
housekeeping gene GAPDH, and Student’s t-test was used to compare paired data sets. 
Statistical significance was accepted at p < 0.05. U2OS osteosarcoma cells cultured under 3D 
condition were found to have a significant increase in the expression levels of  IL-8 and VEGF-A 
(p = 0.049, and 0.017 respectively) (Figure 4.4), with the upregulation of IL-8 being 
tremendously higher than that of VEGF-A. bFGF was mildly downregulated for U2OS cells in 
3D conditions (p = 0.013), while HIF-1α showed no significant difference compared to the 2D 





Figure 4.4. Effect of substrate architecture on angiogenic factor expression by U2OS cells grown in 2D 
T-75 flasks and 3D silk scaffolds. (*Statistically different at p < 0.05.) 
 
4.3.3 Effect of Co-culture with Immortalized Fibroblasts on Angiogenic 
Factor Expression 
Figure 4.5 shows the fluorescence microscopy image of U2OS cells tagged with GFP co-cultured 
with immortalized fibroblasts in a 2D co-culture system, with the formation of islands of U2OS-
GFP cell clusters. Some fibroblasts were found to be spindle-shaped, while others had branched 







































Figure 4.5.  Fluorescence microscopy image of U2OS cells transfected with GFP and co-cultured with 
immortalized fibroblasts. Scale bar = 250 µm. 
 
Three different co-culture conditions were used to investigate the effect of stromal fibroblast co-
culture on the angiogenic factor secretion profiles of the in vitro tumor models. For the 2D co-
culture models, fibroblasts were added into the culture system after U2OS or U2OS-GFP cells 
formed cell clusters. Real-time PCR was performed on U2OS cells transfected with GFP to 
determine the cell-specific perturbations that occurred due to co-culture exposure. When 
compared to the unsorted 2D condition, there was a mild upregulation of both bFGF and VEGF-
A, with p = 0.032 and 0.024 respectively. On the other hand, the expression level of HIF-1 was 
similar in both cases. U2OS co-cultured with fibroblasts showed a marked upregulation of IL-8 
as compared to 2D monoculture, and these results suggest that the co-culture with stromal 






Figure 4.6.  Effect of co-culture with stromal fibroblasts on angiogenic factor secretion by 2D U2OS 
monoculture, 2D GFP-sorted U2OS co-cultured with fibroblasts, and 2D unsorted U2OS co-cultured with 
fibroblasts. *Statistically different at p < 0.05. 
 
When the secretion profiles for 2D unsorted U2OS co-cultured with fibroblasts were compared 
with 3D unsorted U2OS co-cultured with fibroblasts, VEGF-A was only slightly upregulated 
while there was a striking upregulation of IL-8 in the transition from the 2D to 3D co-culture 











































Figure 4.7. Effect of co-culture with stromal fibroblasts on angiogenic factor secretion by 2D unsorted 
U2OS co-cultured with fibroblasts and 3D unsorted U2OS co-cultured with fibroblasts. *Statistically 
different at p < 0.05. 
 
Real-time PCR conducted for IL-8 expression under the various conditions showed that the 
upregulation of IL-8 under the 3D co-culture model was higher than that of the unsorted 2D 
model and 3D monoculture models combined (Figure 4.8). Thus, the large upregulation of IL-8 
under the 3D co-culture model was not simply due to an additive effect of 3D culture and 2D co-
culture, but likely a synergistic outcome of both those factors combined, thereby highlighting the 
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Figure 4.8 Effect of 3D architecture and co-culture on IL-8 expression. 
 
4.3.4 Effect of Co-culture with HUVECs on Angiogenic Factor Expression 
Figure 4.9 shows GFP-transfected U2OS cell clusters co-cultured with HUVECs at confluence. 
The HUVECs surrounding the fluorescent U2OS islands retained their spherical shapes. 
 
 


















































Real-time PCR was then conducted on the co-cultured cells. There was no significant 
upregulation of VEGF-A when U2OS cells were co-cultured with HUVECs in 2D for both the 
sorted and unsorted conditions (p = 0.16 and 0.32 respectively). HUVEC co-culture also did not 
seem to play a major role in IL-8 expression in 2D, with p = 0.076 for the sorted U2OS and p = 
0.014 for the unsorted condition (Figure 4.10). 
 
  
Figure 4.10 Effect of co-culture with HUVECs on angiogenic factor secretion by 2D U2OS monoculture, 
2D GFP-sorted U2OS co-cultured with HUVECs, and 2D unsorted U2OS co-cultured with HUVECs. 
**Statistically similar at p > 0.05. 
 
When real-time PCR was carried out for the 3D monoculture and 3D HUVEC co-culture 
conditions, there was a significant upregulation of both IL-8 and VEGF-A in the 3D HUVEC co-
culture condition (p = 0.024 and 0.0027 respectively). However, this was less than the levels of 











































co-culture appears to suppress angiogenic factor secretion, possibly due to the proximity of the 
endothelial cells to the osteosarcoma cells, and, hence, resulting in a decreased necessity for the 
elevated secretion of angiogenic factors. 
 
 
Figure 4.11 Upregulation of IL-8 and VEGF-A in 3D co-culture with HUVECs. *Statistically different at 
p < 0.05. 
 
4.3.5 Migration of HUVECs through Transwell® Inserts Under the Influence 
of Angiogenic Factors Secreted by U2OS Tumor Models 
Avastin is a recombinant humanized monoclonal antibody to VEGF-A. However, therapies 
involving Avastin have only shown modest clinical success. Likewise, treatment of the 3D tumor 
constructs with Avastin only resulted in a slight decrease in HUVEC migration (Figure 4.12). In 
contrast, a significant drop in HUVEC migration across the Transwell® insert was observed 
when the 3D monoculture model was treated with anti-IL-8 monoclonal antibody despite there 










































IL-8 plays, as compared to VEGF-A. The results obtained using the Transwell® migration 
assays also demonstrate the real-world effect of IL-8 on tumor-associated angiogenesis and 
suggest that the emphasis on anti-VEGFA therapy should be shifted to an emphasis on anti-IL8 
therapy in clinical application. A summary of the percentage of the membrane covered by 
migrated HUVECs is given in Table 4.1. 
 
 
Figure 4.12 HUVEC migration through the Transwell® inserts for untreated 3D monoculture (left), 3D 
monoculture treated with 1 µg/mL anti-VEGF-A monoclonal antibody (center), and 3D monoculture 
treated with 1 µg/mL anti-IL-8 monoclonal antibody (right) (Olympus IX71 microscope, DAPI staining, 
WU filter, Scale bar = 500 µm). 
 







8.40% 7.97% 2.93% 
 
 
Anti-IL-8 monoclonal antibody was then tested on the co-culture models. For the control 
conditions, there was a significant increase in HUVEC migration under the influence of the 3D 
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monoculture tumor construct as compared to the 2D model, due to the upregulation of IL-8 
expression under the 3D culture condition (Figure 4.13). Co-culture with fibroblasts led to a 
slight increase in HUVEC migration for both the 2D and 3D models, reflective of the IL-8 
expression profiles seen in Figure 4.8, and treatment of these co-culture models with anti-IL-8 
monoclonal antibody had no effect on the 2D co-culture model, while the migration of HUVECs 
towards the 3D co-culture model was dramatically reduced. This highlights the importance of the 
architecture in which the tumor cells are cultured in on the efficacy of anti-angiogenic therapy, 
and makes a strong case for the use of anti-IL-8 therapy in the prevention of tumor-associated 
angiogenesis. A summary of the percentage of the membrane covered by migrated HUVECs is 





Figure 4.13 HUVEC migration through Transwell® inserts for (a) 2D monoculture (left), 2D co-cultured 
with fibroblasts (center), and 2D co-cultured with fibroblasts treated with 1 µg/mL anti-IL-8 monoclonal 
antibody (right) and (b) 3D monoculture (left), 3D co-cultured with fibroblasts (center), and 3D co-
cultured with fibroblasts treated with 1µg/mL anti-IL-8 monoclonal antibody (right) (Olympus IX71 
microscope, DAPI staining, WU filter, Scale bar = 500 µm). 
 
Table 4.2 Percentage of membrane covered by migrated HUVECs. 
2D U2OS 
2D U2OS with 
fibroblasts 




5.96% 11.31% 12.38% 
3D U2OS 
3D U2OS with 
fibroblasts 











The upregulation of IL-8 and VEGF-A, and the downregulation of bFGF by U2OS cells grown 
in the 3D silk scaffolds is similar to that obtained using 143.98.2 cells in Chapter 3. This 
highlights the robustness of the 3D tumor model used, and it is highly likely that these silk 
scaffolds can also be implemented in 3D models for epithelial cancers such as breast and prostate. 
Moreover, the increased expression of angiogenic factors suggests that the 3D tumor models are 
able to induce angiogenesis with a higher density of blood vessels, thereby increasing the 
metastatic potential of the tumor cells [15, 85, 227]. 
 
The increase in the expression level bFGF in the 2D co-culture systems as a result of co-culture 
with immortalized fibroblasts could indicate increased tumor agressiveness when in the prescene 
of stromal fibroblasts, the heterogenous tumor now able to recapitulate key conditions in tumor 
development. Studies have found bFGF to be a mitogenic, angiogenic, and neurotrophic factor 
commonly expressed by many types of tumors, and elevated expression of bFGF and VEGF-A 
have been associated with advanced tumor staging in human neuroblastomas [228-230]. The 
upregulation of IL-8 in the 2D co-culture systems are also in line with a previously published 
study that demonstrated a two-fold increase in IL-8 expression levels in LS174T colon cancer 
cell lines co-cultured with colon-derived fibroblasts [231]. IL-8 has been reported to act on 
VEGFR-2, resulting in the upregulation of mRNA and protein expression of VEGF-A in a 
process independent of HIF-1 [232, 233]. IL-8 has also been established to have the ability to 
promote tumor-associated angiogenesis through a VEGF-independent pathway, suggesting that 




Recent studies have suggested that enhanced IL-8 expression may be related to changes in cell 
morphology. Alterations of the actin cytoskeleton have been found to lead to the differential 
activation of NFB, a transcription factor that induces IL-8 expression [235]. It has been 
postulated that IL-8 expression, integrin engagement, and cell morphology are interrelated, 
thereby resulting in the upregulation of IL-8 under 3D culture [236]. There has been increasing 
evidence that IL-8 has a much more crucial role in tumor-associated angiogenesis than 
previously assumed, thus, the resulting upregulation of IL-8 in these 3D monoculture and 
fibroblast co-culture tumor models may offer a more reliable model for drug testing, especially 
for metastatic tumors. 
 
The results for the comparison study between anti-VEGF-A and anti-IL-8 treatment on HUVEC 
migration show that IL-8 plays a more crucial role in endothelial cell migration than VEGF-A. 
VEGF-A and anti-VEGF therapy have been widely established and traditionally targeted in 
cancer research, however, these results suggest that a shift into anti-IL-8 treatment modalities 
could prove to be highly efficacious. Multiple small-molecule inhibitors and humanized 
monoclonal antibodies are now emerging as possible therapeutic approaches to attenuate IL-8 
and its receptors, so as to curb disease progression and modulate the response to combination 
chemotherapy in preclinical models [74]. However, targeting IL-8 expression through either 
humanized monoclonal antibodies against IL-8 or small interfering RNA strategies does not 
account for the effects of other CXC chemokines in the tumor microenvironment. Thus, it has 
been postulated that receptor-targeted strategies which eliminate the entire cascade of chemokine 
signaling may prove to be more efficacious than agents that solely dampen the effects of IL-8 
[237]. CXCR1 and CXCR2 have been suggested as prime targets for small-molecule inhibitors, 
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and the deletion of CXCR2 in the tumor microenvironment has been shown to profoundly affect 
colon cancer growth and angiogenesis, and even increasing intra-tumoral necrosis [74, 238-242]. 
 
4.5 Conclusions 
In this study, it was demonstrated that the co-culture of U2OS cells with immortalized fibroblasts 
led to the upregulation of angiogenic factors, particularly IL-8. This was especially pronounced 
when combined with the effects of the architecture of the 3D silk scaffold. On the other hand, co-
culture with endothelial cells did not lead to increased angiogenic factor production, and instead 
led to a downregulation of IL-8 and VEGF-A under 3D co-culture. The importance of fibroblast 
co-culture and IL-8 production was highlighted when the migration of HUVECs through the 
Transwell® polycarbonate inserts increased for the 3D and co-culture models, and the targeted 
inhibition of IL-8 greatly reduced HUVEC migration despite the presence of VEGF-A. Thus, 
this 3D tumor co-culture model is likely a better preclinical model for drug testing, and stands to 
help bridge the gap between conventional 2D models and animal xenograft models. This 
research also has significant implications on the use of anti-angiogenic therapy targeting VEGF-








Chapter 5                                  
Three-dimensional Spatial 
Configuration of Tumor Cells and 
its Effect on Proliferation and 









The general optimism surrounding the in vitro efficacy of a tumoricidal agent is often met with 
clinical disappointment and this lack of reliable preclinical models has hampered anticancer drug 
discovery. Preclinical protocols are routinely carried out using cells grown 2D culture systems 
that lack the mechanical and molecular features of the 3D microenvironment and use isolated 
subpopulations that ignore the complex, heterogeneous spatial nature of the tumor [7-9, 243]. 
However, many of the characteristics of cells in 2D culture do not translate into the findings in 
animal xenografts [6, 14, 102, 244, 245]. 3D growth may be responsible for some of these 
changes and models using cells grown in 3D may form a more representative step in tumoricidal 
validation prior to animal implantation and human testing.  
 
It was suggested in Chapter 3 that the 3D configuration resulted in reduced proliferation. This 
would be expected to confer chemoresistance as most chemotherapeutic drugs target actively 
diving cells. In this chapter, 143.98.2, SaOS2, or U2OS osteosarcoma cells were seeded on 
porous Bombyx mori silk sponges and cultured in standard static fluid environments. Real-time 
PCR was conducted on cells grown in 2D culture and 3D scaffolds for the proliferation markers 
cyclin B1, E2F1, and p21, as well as the actin regulator RhoA. DNA quantity in the scaffolds 
over the culture period was also measured and cell cycle analysis was carried out for cells grown 
in 2D monolayer and 3D scaffolds. Doxorubicin and cisplatin are commonly administered 
chemotherapeutic drugs for osteosarcoma patients and were used in the cytotoxicity studies 




5.2 Materials and Methods 
5.2.1 Culture of Osteosarcoma Cells on Scaffolds 
Half a million SaOS2, U2OS, or 143.98.2 osteosarcoma cells (ATCC, VA, USA) were 
suspended in 30 µL of complete culture medium and injected into the silk scaffolds. McCoy's 5A 
modified medium (Sigma-Aldrich, MO, USA) containing 15% fetal bovine serum and 1% 
penicillin/streptomycin used used for SaOS2 and U2OS cell lines, while Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen, CA, USA) supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin was used for the 143.98.2 cell line (ATCC, VA, USA). The scaffolds 
were cultured in 6-well suspension plates with their respective culture mediums for 7 days and 
incubated at 37°C and 5% CO2 (Model 3111, Forma Scientific, OH, USA). For live cell imaging, 
scaffolds were sliced and stained with 2 mL of culture medium containing 6 µL of 5 mg/mL 
fluorescein diacetate (FDA, Molecular Probes, OR, USA) after 1 day of culture and viewed 
under an Olympus IX70 phase contrast microscope. 
 
5.2.2 DNA Quantification and Cell Metabolic Activity 
For DNA quantification using PicoGreen, the scaffolds seeded with half a million U2OS cells 
and cultured as in Section 5.2.1 were rinsed with ice-cold PBS before being placed in cryovials 
and stored in liquid nitrogen. The scaffolds were then freeze-dried and disintegrated. 
Homogenization was performed with 400µL of lysis buffer (Qiagen, CA, USA). The tubes were 
agitated for 5 mins and centrifuged at 16,000 rpm for 5 mins. 20µL of the supernatant was added 
to 80µL of 200×-diluted PicoGreen in each well of a black 96-well plate. Fluorescence intensity 
was measured at 520 nm. AlamarBlue® assay (Invitrogen, CA, USA) was conducted on days 1, 
3, 5 and 7 to ensure the cells remained viable (n = 3). 1.5 mL of McCoy's 5A modified medium 
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containing 10 % (v/v) alamarBlue and 5% (v/v) fetal bovine serum was pipetted into each well of 
a 6-well plate and incubated for 3 hours. After incubation, 200 μL of the solution in each well 
was pipetted into a 96-well plate and transferred to a micro-titer plate reader (Sunrise, Tecan, 
Switzerland). Absorbance measurement was then taken at 570 nm and 600 nm and the 
percentage reduction was calculated. Student’s t-test was used to compare paired data sets. 
Statistical significance was accepted at p < 0.05. 
 
5.2.3 Cell Cycle Analysis 
The cells cultured in the scaffolds from Section 5.2.1 were trypsinized and fixed in 70% ethanol 
at 4°C on day 7 (n =3). Cells were incubated with 0.1% Triton X-100, 0.2 mg/mL RNase A and 
20 µg/mL propidium iodide at 37ºC for 15 mins. Cell cycle analysis was carried out using a 
Cyan ADP analyzer (LX538R, Beckman Coulter, CA, USA) and stopped at 10,000 events. The 
data for cells grown in the 3D scaffolds for 7 days was compared to cells grown in the 2D 
polystyrene T-75 culture flasks and cells reseeded from the scaffolds onto the 2D flasks. 
 
5.2.4 Gene Expression Profiling 
RNA from the cells grown in 2D culture and 3D scaffolds was extracted using TRIzol reagent 
(Invitrogen, CA, USA) and purified with an RNeasy mini spin column (Qiagen, CA, USA). 
cDNAwas synthesized using the iScriptcDNA synthesis kit according to the manufacturer’s 
instructions (Bio-Rad Laboratories, CA, USA). Real-time PCR was conducted using the iQ 
SYBR Green Supermix (Bio-Rad Laboratories, CA, USA) with the primers in Table 5.1. 
Standard descriptive statistics were used: mean and standard deviation were determined with 
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respect to GAPDH. Student’s t-test was used to compare paired data sets. Statistical significance 
was accepted at p < 0.05. 
 
Table 5.1 Table of primers. 
Gene Name Forward Primer Backward Primer 
Cyclin B1 5’-GCC TAT TTT GGT TGA TAC 
TGC-3’ 
5’-ATC TGT CTG ATT TGG TGC 
TTA GT-3’ 
E2F1 5'-CAT CCA GCT CAT TGC CAA 
GAA G-3' 
5'-GAT CCC ACC TAC GGT CTC 
CTC A-3' 
RhoA 5'-AGA GGT GTA TGT GCC 
CAC AGT-3' 
5'-CTT CGG AAT GAT GAG CAC 
AC-3' 
MDR1 5'-TAC AGT GGA ATT GGT 
GCT GG-3' 
5'-CTA ATT GCT GCC AAG ACC 
TC-3' 
p21 5'-TGG AGA CTC TCA GGG 
TCG AAA-3' 
5'-CGG CGT TTG GAG TGG TAG 
AA-3' 
GAPDH 5'-GAG TCA ACG GAT TTG 
GTC GT-3' 
5'-CAT GGG TGG AAT CAT ATT 
GGA-3' 
 
5.2.5 DNA Gel Electrophoresis 
DNA gel electrophoresis was carried out using the PCR product from the E2F1 and cyclin B1 
secretion profiles. 7.5 µL of PCR product and 1.5 µL of loading dye was pipetted into each well 
of a 2% (w/v) agarose gel, and 5 µL of DNA ladder and 1µL of loading dye was used for the 
ladder. Ethidium bromide was added to the TAE running buffer at 0.25 µg/mL and the gel was 
run at 100V for 1 h (PowerPac Universal, Bio-Rad Laboratories, CA, USA). The gel was 
illuminated with a UV transilluminator (Wealtec, NV, USA), imaged with an Olympus C-5060 
camera, and processed using AlphaEase FC software (Alpha Innotech, CA, USA). 
 
5.2.6 Cytotoxicity Testing with Doxorubicin or Cisplatin 
For 2D testing, a 96-well plate was seeded at 2,000 cells per well and incubated with 200 µL of 
culture medium for 24 h. The wells were washed with PBS. 200 µL of serial dilutions of 
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doxorubicin or cisplatin were added at 0.001 µg/mL to 100 µg/mL to each well. After 24 h, the 
wells were washed with PBS, topped up with 200 µL of fresh culture medium, and further 
incubated for 24 h. The wells were then washed with PBS, and 250 µL of medium containing 10% 
alamarBlue was added and the wells incubated for 3 h. 200 µL per well was then pipetted into a 
new 96-well plate and absorbance measurements were taken at 570 nm and 600 nm. The relative 
viability was calculated by normalizing to the untreated osteosarcoma cells. For 3D testing 
seeded scaffolds from Section 5.2.1 were placed in 1.5 mL of culture medium containing serial 
dilutions of doxorubicin or cisplatin at 0.1 µg/mL to 100 µg/mL for 24 h after 6 days of culture. 
The scaffolds were then washed with PBS and placed in 1.5 mL of fresh culture medium for 24 h. 
Following which, the scaffolds were washed with PBS and placed in 1.5 mL of culture medium 
with 10% alamarBlue® for 3 h. After incubation, triplicates of 200 μL of the solution in each 
well were pipetted into a 96-well plate and the relative viability was calculated from absorbance 
measurements taken at 570 nm and 600 nm. 
 
5.3 Results 
5.3.1 Good Permeability of the Silk Scaffolds  
It took under 30 seconds for the dye to diffuse throughout the scaffold, highlighting the high 
permeability of the silk material (Figure 5.1). Further, there were no pockets where dye was 




Figure 5.1 Longitudinal section of a scaffold showed complete penetration of the dye in under 30 seconds. 
 
5.3.2 Growth Patterns in 2D Monolayers and 3D Tumor Constructs 
The U2OS cells transitioned from a cuboidal, epithelial-like cell morphology when cultured on 
2D T-75 polystyrene flasks and silk cast films to a more spindle shape morphology on the silk 
scaffold, reflective of the in vivo cell morphology of neoplasms of mesenchymal derivation 
(Figure 5.2a-c). Fluorescein diacetate live cell staining conducted 1 day after cell seeding 






Figure 5.2 (a) Phase contrast microscopy image of U2OS cells on a 2D T-75 flask on (from left) day 1 
and 3 of culture. Scale bar = 250 µm. (Olympus IX70) (b) Phase contrast microscopy image of U2OS 
cells on 2D silk cast films on (from left) day 1 and 3 of culture. Scale bar = 250 µm. (Olympus IX70) (c) 
102 
 
3D silk scaffold seeded with U2OS cells after 7 days of culture, stained with hematoxylin. Scale bar = 
500 µm. (Olympus IX70) (d) Fluorescein diacetate live cell staining for U2OS cells seeded on the 3D silk 
scaffold after 1 day of culture. (Olympus IX70, WB filter) Scale bar = 250 µm. 
 
5.3.3 G1 arrest by cells cultured in the 3D scaffolds 
PicoGreen DNA quantification was conducted over the culture period on days 1, 3, 5 and 7 and 
the DNA concentration was determined by comparing the readings to a standard curve for known 
cell counts. The total DNA concentration of the U2OS cells seeded in the 3D scaffolds remained 
constant throughout the 7 days of culture, suggesting that the cells seeded in the 3D scaffolds 
were experiencing cell cycle arrest (Figure 5.3a). Despite the lack of increase in proliferation, the 
cells remained viable during the culture period, as seen from the increasing percentage reduction 
of alamarBlue and, hence, the metabolic activity of the cells, over the first 5 days of culture 
before it eventually plateaued off at day 7 (Figure 5.3b). Histology showed that U2OS cells were 








Figure 5.3 (a) PicoGreen assay for porous silk scaffolds seeded with U2OS cells over 7 days of culture 
from Section 4.3.1. (b) AlamarBlue assay for U2OS cells seeded in porous silk scaffolds over 7 days of 
culture. (c & d) Hematoxylin & eosin staining for U2OS distribution on 3D silk scaffolds at the center of 
the scaffold at day 7. Scale bar = 200µm. 
 
Cell cycle analysis showed that the total percentage of cells in S phase and G2 phase for 2D 
monolayer culture was reflective of the doubling time of the cell lines, with the most rapidly 
proliferating 143.98.2 cell line having the highest combined percentage of cells in S phase and 
G2 phase (Figure 5.4a). There was a decrease in the percentage of the total viable cell population 
that was in G2 phase as compared to 2D monolayer culture when the osteosarcoma cells were 




in the cell cycle where the DNA is replicated, the results from the cell cycle analyses for 3D 
culture are in line with the data for PicoGreen obtained in Figure 5.3a, where the total amount of 
DNA failed to increase over time. Most significantly, G1 arrest was observed in all cell lines 
under 3D culture, further explaining the lack of tumor growth in the 3D constructs. The cells 
were able to exit G1 arrest once they were reseeded back onto 2D polystyrene culture flasks, 
suggesting that the 3D architecture did not permanently alter growth kinetics (Figure 5.4b). 
Taken together, the results suggest that growth in 3D spatial geometry causes tumor cells to 
divert cellular activity away from a generally proliferative state. 
 
 
Figure 5.4 (a) Gated flow cytometry cell cycle analysis for SaOS2 (left), U2OS (center), and 143.98.2 
(right) cells grown on 2D polystyrene flasks (top) and 3D silk scaffolds (bottom), with the percentage of 
cells in each phase of the cell cycle indicated. (b) Gated flow cytometry cell cycle analysis for SaOS2 
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(left), U2OS (center), and 143.98.2 (right) cells on 2D polystyrene flasks after being reseeded from 3D 
silk scaffolds. 
 
5.3.4 Downregulation of proliferation markers by cells in the 3D scaffolds 
DNA gel electrophoresis was performed on the proliferation markers cyclin B1 and E2F1 from 
PCR product of the RNA extracted from U2OS and 143.98.2 cell lysates. A decrease in intensity 
of the bands was observed for cyclin B1 and E2F1 in the 3D scaffold condition for both 143.98.2 
and U2OS cell lines (Figure 5.5a-b). Quantitative real-time PCR showed that the expression 
levels of cyclin B1 and E2F1 by 143.98.2 and U2OS cells grown in the 3D silk scaffolds was 
significantly downregulated as compared to 2D culture (Figure 5.5c). The p values for 143.98.2 
for cyclin B1 and E2F1 were 0.02 and  0.001 respectively, while U2OS had p values of 0.02 





Figure 5.5 (a) Quantitative real-time PCR for proliferation markers cyclin B1 and E2F1 expressed by 
143.98.2 and U2OS cells grown in 2D culture or 3D silk scaffolds normalized to GAPDH expression. (b) 
DNA gel for cyclin B1, with GAPDH as the housekeeping gene. (c) DNA gel for E2F1. *Statistically 
different at p < 0.05. 
 
U2OS and 143.98.2 cells also significantly downregulated their expression of RhoA when 
cultured on the 3D silk scaffolds as compared to when they were plated on polystyrene T-75 
culture flasks, with p = 0.008 for 143.98.2 and p = 0.02 for U2OS (Figure 5.6a). There was also a 
significant upregulation of p21 in 3D culture (p  0.001 for SaOS2 and U2OS), which 
corroborates with the downregulation of E2F1 as p21 is regulated by E2F1 at the G1 checkpoint 
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(Figure 5.6b). These results confirmed the observations that 3D growth resulted in a non-
proliferative phenotype. There was also no significant increase in MDR1 when the cells were 
grown in the 3D scaffolds, indicating that scaffold culture did not result in an increase in 
multidrug resistance, only cell cycle arrest.  
 
Figure 5.6 (a) Quantitative real-time PCR for RhoA expressed by 143.98.2 and U2OS cells grown in 2D 
culture or 3D silk scaffolds. (b) Quantitative real-time PCR for p21 and MDR1 expressed by 143.98.2 and 
U2OS cells grown in 2D culture or 3D silk scaffolds. *Statistically different at p < 0.05. 
 
5.3.5 Three-dimensionally cultured osteosarcoma cell lines were less sensitive 
to doxorubicin treatment 
Cytotoxicity evaluation using doxorubicin was carried out for 143.98.2, U2OS, and SaOS2 cells 
grown in 2D in 96-well plates and in 3D while seeded on the silk scaffolds (Figure 5.7a-c). The 
osteosarcoma cells were less susceptible to the doxorubicin treatment when grown in the 3D 
scaffolds for all cell lines, as seen from the alamarBlue® assay results where there was an 
approximately 100-fold difference in the IC50 values between the two conditions. The large 
difference in drug sensitivity was not due to insufficient drug penetration into the scaffold, as the 




Figure 5.7 Cytotoxicity results for (a) 143.98.2 cells, (b) U2OS cells, and (c) SaOS2 cells treated with 




5.3.6 Similar cytotoxicity results for both 2D and 3D culture when cells were 
treated with cisplatin 
The effect of cisplatin, being a non-cell-cycle specific agent would be anticipated to be less 
dramatic than the results for doxorubicin. In fact, the results obtained for chemotherapeutic 
evaluation using cisplatin in 2D and 3D culture were very similar, with the cells grown in the 3D 
scaffolds having less than a 10-fold decrease in sensitivity to cisplatin treatment as compared to 





Figure 5.8 Cytotoxicity results for (a) 143.98.2 cells, (b) U2OS cells, and (c) SaOS2 cells treated with 





Microenvironmental conditions regulate tumorigenesis and tumor aggressiveness, thus, a 
biomimetic culture system for use in the modeling of tumors in vitro may greatly facilitate the 
study of the dependency of cancer cells on these conditions [15, 223, 224, 246]. Local 
mechanical interaction between the cell and its microenvironment may be the unifying principle 
that connects micro- and macro-scale tissue architecture with cell shape, organization and 
differentiation [246]. The cells interpret variations in the compliance of the ECM through 
integrins, which connect to the cytoskeleton and translate the external mechanical information 
into the modification of cell contractility, primarily by controlling the activity of Rho GTPases 
[247]. Rho GTPases are key regulators of focal complex and focal adhesion assembly, cell 
motility, cell polarity and cell cycle progression, many of which are involved in and/or 
deregulated in cancer growth and metastasis. Overexpression of RhoA can induce DNA 
synthesis either independent of or in cooperation with Ras [190]. It is hypothesized that the 
transition from a 2D to 3D architecture resulted in a downregulation of RhoA, leading to a 
downstream inhibition of E2F1, cyclin B1, and ROCK expression, and ultimately G1 cell cycle 
arrest. Changes in the mechanical architecture of the ECM influences the cell-matrix interaction 
and focal adhesions, leading to alterations in Rho GTPase signaling involved in the transmission 
of mechanical forces through the cytoskeleton, which results in changes in cell proliferation 
[246]. 
 
Furthermore, RhoA activation has also been shown to remove the inhibition of cell-cycle 
progression by p21 and p27 [246, 248, 249]. G1 arrest by cancer cells when grown in 3D has 
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previously been reported in multicellular spheroids for colon, mammary and ovarian tumors, as 
well as other cell types [112, 250, 251]. Roncoroni et al. noted that the difference is related more 
to a change in cell cycle phase distribution rather than cell distress as lower scatter signals in 3D 
than in the 2D cultures were found in all the cell lines [112]. The cell cycle analysis observation 
that cells grew exponentially when osteosarcoma cells from the 3D scaffolds were reseeded in 
2D culture was in accordance with their data, suggesting that 3D culture did not alter the growth 
kinetics of the cells (Figure 5.4 b). 
 
The conclusions of the above studies are in line with the findings that growth in 3D scaffolds 
results in G1 arrest in osteosarcoma cells. The expression of cyclin B1 and E2F1 by 143.98.2, 
U2OS and SaOS2 osteosarcoma cells grown in the 3D silk scaffolds was significantly reduced as 
compared to 2D culture, and this coupled with the G1 arrest by cells grown in 3D suggested that 
the cells grown in 2D would be more sensitive to cell cycle specific agents. Doxorubicin and 
cisplatin are commonly administered in chemotherapy for osteosarcoma patients and doxorubicin 
is a cell cycle specific chemotherapeutic drug while cisplatin is cell cycle non-specific. As 
predicted, the cytotoxicity assays for the osteosarcoma cells cultured in the presence of 
doxorubicin showed that the cells in 2D monolayer culture were more sensitive to doxorubicin 
than in the 3D scaffolds due to the targeting of actively dividing cells by doxorubicin. In contrast, 
the graphs for cisplatin-treated cells were more similar for the 2D and 3D cultures, due to the 
non-specific action of cisplatin. The results for the 3D model were still largely in the 
physiologically relevant range of 0.04 to 4 µg/mL, while the 2D model resulted in cell 
populations that were too sensitive to the drugs used [210, 252, 253]. In a study by Martin and 
McNally, fluorometric measurements of the average amount of doxorubicin in mouse 
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osteosarcoma tumors 4, 9 or 28 h after intraperitoneal injection of 9 mg/kg of the drug gave 
levels of 12, 4 and 0-25 µg/g respectively [254]. These levels would cause massive cell kill in 
vitro for cells in 2D culture. The study also found that a dose of 4 µg/ml of doxorubicin for 1 h to 
the in vitro two-dimensionally cultured tumor cells would reduce the surviving fraction to well 
below 10
-3
. Cells in plateau phase were found to be significantly more resistant than cells in log-
phase and an in vitro mean lethal dose of 0.1 µg/ml was found for mouse tumor cells, which was 
in line with the results using HeLa cells, Chinese hamster ovary cells and V79 cells investigated 
by other groups. The figures found in the in vivo experiments of this study are in agreement with 
the values obtained using the 3D model, thereby validating the results obtained in this chapter. 
 
The silk scaffolds used have high permeability, as seen from the rapid diffusion of the dye into 
the scaffold, hence, it is unlikely that the large differences in chemosensitivity seen were a result 
of diffusion rates alone (Figure 5.1). Thus, this unique construct represents a specific model of 
the cellular effects of 3D architecture without the specific effects of drug penetration, delivery, 
and flow-related perturbations of blood flow, fluid convection or solute conduction. Miller et al. 
showed that mammary tumor cells grown as boluses in collagen gels were able to continue to 
expand in the presence of drug concentrations that allowed the survival of less than 0.1% of the 
cells in a cloning assay. This increased resistance was not due entirely to differences in drug 
delivery or the penetration of drug into the gel as similar differences between the assays 
appeared when the cells were treated with doxorubicin, melphalan or 5-fluorouracil in monolayer 
culture prior to being embedded in the collagen. It was also postulated that there may be a 
subpopulation within each cell bolus which is drug resistant due to its lowered rate of cell 
division, a result of changes in the oxygenation, pH, etc. in its microenvironment, or even 
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metabolic changes in the cell triggered by cell shape or degree of differentiation [249]. It was 
previously observed that there were significant decreases in oxygenation and pH when 
osteosarcoma cells were cultured in these silk sponges [227]. A previous publication by Xing et 
al. showed an association of chemoresistance with the 3D configuration when they found that P-
glycoprotein and MDR1 were not expressed in monolayer cells but significantly elevated in 
multicellular spheroids of ovarian cancer cells, and postulated that non-cycling cells may survive 
antitumor treatment and subsequently reproliferate [251]. However, the evaluation of the cell 
lines used does not show a significant change in MDR1 expression relative to this 3D change. 
The main line of perturbations suggest that the resistance phenomenon is a state of replicative 
quiescence secondary to the 3D configuration and not the development of an excretory function 
of P-glycoprotein secondary to MDR upregulation. Taking all factors into account, this 3D 
model has the potential to be used in the development of moieties with lower drug sensitivities 
for the evaluation of drugs that require higher doses for therapeutic effect. 
 
5.5 Conclusions 
The cytotoxicity results suggest that the cytotoxic drug sensitivity of osteosarcoma cells is 
largely dependent on the architecture in which the cells are cultured in, as this affects the rate of 
proliferation of the cultured cells. The 3D tumor construct can be used to help bridge the gap 
between in vitro and in vivo studies to improve the yield and quality of high throughput cytotoxic 
drug screening, cell-based assays, and ex vivo drug testing during the drug discovery phase, 












Chapter 6                          
Pressurized Bioreactor Studies and 













In the previous chapters, it was shown that the 3D engineered tumor constructs had elevated 
expression of angiogenic factors and decreased proliferation rates. These scaffolds will now be 
implanted in SCID mice to investigate if these characteristics are maintained in the in vivo 
environment. The scaffold tumors are also hypothesized to possess lower IFP, thus, comparing 
these tumors to the standard injected heterogenous SCID mouse xenograft tumors with intrinsic 
elevated IFP would allow for the further validation of the theory that elevated IFP plays a role in 
the regulation of HIF-1 production. In vivo pressure readings were taken in the injected tumors 
and the scaffold tumors and used when analyzing the immunohistochemical staining results 
obtained from these two tumor types. Avastin at a dose of 5 mg/kg was injected into groups of 
mice with either the injected tumors or the scaffold tumors and histology was carried out to 
investigate the effect of Avastin on blood vessel formation. A perfusion bioreactor that was able 
to mimic the in vivo IFP was designed and fabricated for long-term culture of the tumor 
constructs. Scaffolds were cultured in the perfusion bioreactor and the expression profiles were 
compared to the injected tumors to verify if the in vitro bioreactor model was a good 
approximate to the standard subcutaneous heterogenous in vivo model. 
 
6.2 Materials and Methods 
6.2.1 Perfusion Bioreactor Design 
Engineering drawings for the bioreactor chambers are given in Figure 6.1 (a). The chambers 
were made of polycarbonate with a 5-mm diameter depression in the center to house the scaffold 
(Figure 6.1 (b)). Figure 6.1 (c) shows a diagrammatic drawing of the set-up of the perfusion 
bioreactor. Masterflex Tygon lab tubing #25 was used for the circuit, except for the section in 
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contact with the peristaltic pump (BT100-1L, LongerPump, China), which was Masterflex 
Pharmed tubing #25 instead. A Discofix 3-way stopcock (B. Braun, Germany) was used to 
connect the 30-mL syringe (Terumo, Tokyo, Japan) to the Masterflex Tygon lab tubing #25. 2 x 
10
6
 143.98.2 osteosarcoma cells (ATCC, VA, USA) were seeded in each of the 4 scaffolds and 
cultured statically for 3 days prior to being placed in the bioreactor chamber. Each of the 4 
chambers was held securely by the polycarbonate base. 125 mL of DMEM culture medium 
(Invitrogen, CA, USA) containing 10% fetal bovine serum (GIBCO) and 1% 
penicillin/streptomycin (PAN Biotech GmbH, Aidenbach, Germany) was pipetted in each 
reservoir and the pump was allowed to run at a speed of 143.6 µL/min for 1, 2, or 3 weeks. The 




        
 
 
Figure 6.1 (a) Engineering drawings of the bioreactor chamber. (b) Chamber housing the 3D tumor 








Figure 6.2 Set-up of the perfusion bioreactor with the chambers and reservoirs (left) and external 
peristaltic pump (right). 
 
6.2.2 Bioreactor Pressure Measurements 
In order to measure the pressure within the bioreactor chambers, a hole 1.2 mm in diameter was 
drilled into each chamber for the insertion of an 18G hypodermic needle. The system was primed 
as in Section 6.2.1 before the flow at Discofix 3-way stopcock 1 was closed off and Discofix 3-
way stopcock 2 was opened. The culture medium was allowed to flow out of the tubing and air 
bubbles were removed before the pressure sensor (Lutron PS100-2BAR, Marcucci S.p.A., Italy) 
was connected to the end of the tubing. Discofix 3-way stopcock 1 was reopened and pressure 
readings were taken when the system reached equilibrium. A diagrammatic representation of the 






Figure 6.3 Diagrammatic representation of modifications for pressure measurements. 
 
 




6.2.3 Analysis of Angiogenic Secretion Profiles by Cells on Scaffolds in the 
Bioreactor 
The chambers were removed from the circuit and the scaffolds were immediately minced and 
lysed in TRIzol reagent (Invitrogen, CA, USA) for RNA extraction, and quantitative real-time 
PCR was conducted for angiogenic markers as in Section 3.2.8 (n = 3). 
 
6.2.4 Subcutaneous Xenograft Tumors in SCID Mice 
All animal experimentation was approved by the National University of Singapore Institutional 
Animal Care and Use Committee (IACUC 048/10). Female SCID mice (n = 5) were obtained at 
the age of 6 weeks and 2 x 10
6
 143.98.2 osteosarcoma cells (ATCC, VA, USA) were suspended 
in 0.2 mL saline and injected subcutaneously between the scapula to form the injected tumors. 
For the scaffold tumors, 2 x 10
6
 143.98.2 osteosarcoma cells (ATCC, VA, USA) were seeded on 
a 3D silk scaffold and cultured for 3 days before being implanted in the mice. The mice were 
induced with 5% isofluorane and 1 L/min oxygen, and later maintained with 1.5% isofluorane 
and 1 L/min oxygen via a nose cone. Fur was shaved off and an incision was made to implant the 
seeded scaffold subcutaneously on the back of the mouse. An unseeded scaffold was 
simultaneously implanted as a control. The incision was closed with a purse-string suture to 
ensure that the knot remained below the skin and, thus, minimize the risk of nibbling at the 
stitches. 0.7 mL of saline was injected subcutaneously post-surgery to help in recovery. 0.005 
mL/g burprenorphine and 0.01 mL/g enrofloxacin were administered twice a day for 3 days and 
the mice were weighed daily for 1 week. Mice were housed individually and food was placed at 
the bottom of the cage for easier access. The mice were euthanized using carbon dioxide gas and 
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tumors were harvested on day 21, or when they reached 15 mm in size (Figure 6.5). The tumors 
were weighed and halved. One half was immediately minced and lysed in TRIzol reagent 
(Invitrogen, CA, USA) for RNA extraction, and quantitative real-time PCR was conducted for 
angiogenic markers as in Section 3.2.7. The other half was fixed in 10% phosphate buffered 
formaldehyde for histology. 
 
 
Figure 6.5 Surgery for scaffold tumors. (a) The mouse was kept anaesthetized with 1.5% isofluorane and 
1 L/min oxygen. The fur was cleaned with iodine before shaving. (b) The scaffold was implanted 
subcutaneously and the incision closed using purse-string suture. (c) The mouse was euthanized at 3 




6.2.5 Avastin Administration to SCID Mice 
The mice were induced with 5% isofluorane and 1 L/min oxygen, and later maintained with 1% 
isofluorane and 1 L/min oxygen via a nose cone on day 14. Avastin was diluted with saline to 5 
mg/kg [255] and injected into the tail vein using a 27G hypodermic needle for both the mice with 
implanted scaffold tumors and injected tumors (Figure 6.6). Mice were sacrificed and tumors 
were harvested at 21 days. The tumors were weighed and fixed in 10% phosphate buffered 
formaldehyde for histology. 
 
 




6.2.6 In Vivo Pressure Readings 
The mice were anaesthetized and pressure readings within the tumor were taken with a 27G 
hypodermic needle attached to a MEMSCAP SP844 pressure transducer (MEMSCAP, France). 
The instrument was primed with saline and calibrated with a pressure gauge while the 
MEMSCAP SP844 pressure transducer was connected to the ADInstruments Powerlab ML880 
(ADInstruments, NSW, Australia) for data logging (Figure 6.7). Tumor pressure readings were 
taken every 2 mm, and an initial reading was taken under the skin as a control according to a 
previously established protocol [212]. 
 
Figure 6.7 In vivo pressure readings. (a) Set-up of instruments. (b) LabChart software. (c) Measurement 
of pressure within the tumor. 
 
6.2.7 Immunohistochemical Staining of SCID Mouse Tumors 
The scaffolds were fixed in 3.7% formaldehyde, embedded in paraffin and sectioned at 7 µm 
slices (RM2135, Leica, Germany). Slides were deparaffined according to standard protocols 
prior to viewing under the microscope (Appendix A). The heat-induced epitope retrieval method 
was used for antigen retrieval. Slides were covered in sodium citrate buffer at pH 6.0 (Dako 
Cytomation, Glostrub, Denmark) and placed in a pressure cooker (T/T Mega Multifunctional 
Microwave Histoprocessor, Milestone, Italy) for 15 mins, which was kindly granted for use by 
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A/Prof. Richie Soong of the Cancer Science Institute. Peroxidase block (Dako Cytomation, 
Glostrub, Denmark) was added to each sample and incubated for 15 min. Ultra V Block (Thermo 
Scientific, MA, USA) was added to all slides except those to be stained for HIF-1 and dabbed 
off after 5 mins. 50 µL of anti-HIF-1α mouse monoclonal IgG (Santa Cruz Biotechnology, CA, 
USA), anti-VEGF-(A-20) rabbit polyclonal IgG (Santa Cruz Biotechnology, CA, USA), mouse 
anti-VEGFR-2 (AbD Serotec, Oxford, UK), anti-IL-8 mouse monoclonal IgG (Santa Cruz 
Biotechnology, CA, USA), or anti-PECAM-1 goat polyclonal IgG (Santa Cruz Biotechnology, 
CA, USA) primary antibody diluted at 1:50 was used and incubated for 1 hour. Labeled 
polymer-HRP anti-mouse (Dako Cytomation, Glostrub, Denmark) for anti-HIF-1 and anti-IL-8 
primary antibodies, labeled polymer-HRP anti-rabbit (Dako Cytomation, Glostrub, Denmark) for 
anti-VEGF-A primary antibody, or Alexa Fluor 594 anti-goat (Invitrogen, CA, USA) secondary 
antibodies was added and incubated for 1 hour. The Alexa Fluor 594 anti-goat secondary 
antibody was provided by A/Prof. Raghunath from the NUSTEP Tissue Modulation Laboratory. 
Slides were washed after each step with PBS. Slides stained for PECAM-1 were viewed under 
the WG filter of an Olympus IX71 microscope. For the remaining slides, 50 µL of DAB+ 
substrate chromogen complex (Dako Cytomation, Glostrub, Denmark) was pipetted onto the 
sample and incubated for 5 min. Hematoxylin staining was performed on sections using standard 
protocols. Slides were dehydrated in an ethanol gradient, cleared in xylene and mounted for 
viewing under an Olympus IX71 microscope (Appendix A). For negative controls, the primary 





6.3.1 Scaffold Tumors were Significantly Smaller than Injected Tumors 
The average weight of the implanted scaffold tumors was 0.75 ± 0.40 g, which was significantly 
less than that of the injected tumors 1.66 ± 0.30 g (p = 0.037, n = 5) (Figure 6.8). This is likely 
due to the culture of the 143.98.2 cells in the 3D silk scaffolds, which was found to result in 
decreased proliferation rates in Chapter 5. The cells seeded on the 3D silk scaffold continued to 
proliferate slower even when transferred to the in vivo model, while the injected cells were 
primed on the 2D T-75 polystyrene flasks and, hence, retained their active proliferation rates in 
the in vivo model. 
 
 
Figure 6.8  Excised injected tumor (left) and scaffold tumor (right) after formalin fixation. 
 
6.3.2 Decrease in Tumor Size for Avastin-treated Tumors 
The mice were injected with 5 mg/kg of Avastin on day 14 and sacrificed on day 21. Figure 6.9 
shows the freshly excised Avastin-treated scaffold tumor and the untreated scaffold tumor from 
the control group. The Avastin-treated tumors were significantly smaller than the untreated 
tumors for both the injected tumors and the scaffold tumors (Table 6.1). The scaffold tumors 
showed a slightly larger decrease in final tumor size (3.75-fold decrease), although the tumors 
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were not drastically smaller than the treated injected tumors (2.24-fold decrease). It was also 
noted that the tumors did not significantly increase in size following the administration of 5 
mg/kg Avastin on day 14. 
 
 
Figure 6.9 Freshly excised Avastin-treated scaffold tumor (left) and untreated scaffold tumor after 
formalin fixation (right). 
 
Table 6.1 Summary of tumor weights at 3 weeks of in vivo culture (n = 3). 
 
Injected Tumor Scaffold Tumor 
No Treatment 1.66 ± 0.30 g 0.75 ± 0.40 g 
Avastin 
Treatment 0.74 ± 0.03 g 0.20 ± 0.05 g 
Decrease in 
Tumor Size 2.24-fold 3.75-fold 
 
 
6.3.3 In Vivo Tumor Pressure Readings 
The average pressure in the center of the scaffold-derived tumors was 10.88 ± 0.86 mmHg, a 
drop from the 25.23 ± 2.71 mmHg measured in the injected tumors in our previous study [212] 
(Figure 6.10). A pressure gradient between the peripheral and central regions of the heterotopic 
tumor was also established in the scaffold tumor, with a peripheral reading of 2.02 ± 0.53 mmHg, 
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which is slightly higher than the 0.96 ± 2.71 mmHg observed in the injected tumors. The 
presence of the 3D scaffold likely conferred some structural support to the scaffold tumor, and 
allowed for a more even distribution of tumor cells and pressure within the tumor. The scaffold 
may have also served as a low fluid resistance sieve, thereby alleviating the excessive 
accumulation of interstitial fluid and IFP. 
 
 
Figure 6.10 IFP readings for SCID mouse xenograft implanted scaffold tumors and injected tumors at 3 
weeks. Tumor IFP was higher in the center of the tumor than in the peripheral region for both tumor types. 
*Statistically different at p < 0.05. 
 
6.3.4 Scaffold Tumors Stained More Intensely for Angiogenic Markers than 
Injected Tumors 
Immunohistochemical staining for HIF-1, IL-8, and VEGF-A was conducted, and scaffold 
tumors were found to have a higher percentage of positively-stained cells for all three factors, as 






















results obtained in Section 3.3.7, where 143.98.2 cells cultured in the 3D scaffolds were found to 
upregulate HIF-1, IL-8, and VEGF-A as compared to the 2D monolayer culture condition. 
Thus, the increased angiogenic factor production that resulted from the culture of the cells in the 
3D scaffold remained when the seeded scaffolds were cultured in vivo, and this led to the 
formation of tumors with increased angiogenic potential. Unlike the injected tumors that stained 
positive for HIF-1 mostly in the periphery of the tumor, the scaffold tumors had HIF-1 evenly 
distributed throughout the tumor. This could be due to the lower IFP present in the center of the 
scaffold tumors, thus, the effect of HIF-1 suppression by elevated IFP as was shown by Khin et 
al. 2012 and Nathan et al. 2008 was less apparent than in the injected tumors. It was further 




Figure 6.11 Immunohistochemical staining for HIF-1, IL-8, and VEGF-A in injected and scaffold 




6.3.5 Administration of Avastin to SCID Mice did not lead to Significant 
Reduction in Angiogenesis 
Immunohistochemical staining was conducted for platelet endothelial cell adhesion molecule 
(PECAM-1, also known as CD31) and the immunofluorescence method was used for detection. 
A more extensive vessel network was observed in scaffold-derived tumors as compared to the 
injected tumors (Figure 6.12), which is reflective of the increased IL-8 and VEGF-A production 
within the scaffold environment. For the group that was treated with Avastin, microvasculature 
networks were still noted for the injected tumors and there was a slight decrease in vasculature 
for the scaffold-derived tumors treated with Avastin. Nevertheless, this could also be due to the 






Figure 6.12 Immunofluorescence images for sections of untreated and treated groups of injected tumors 
and scaffold tumors stained for PECAM-1. Cell nuclei were stained with DAPI (WU filter) and Alexa 





6.3.6 Bioreactor Culture Led to a Downregulation of VEGF-A and IL-8 
Quantitative real-time PCR for angiogenic factors showed that there was no significant 
difference in bFGF and HIF-1 expression when 143.98.2 cells were cultured in the perfusion 
bioreactor versus static 3D culture (Figure 6.13). However, there was a significant 
downregulation in both IL-8 and VEGF-A after 1 week of bioreactor culture compared to cells 
cultured statically over the same duration, likely due the improved perfusion and, hence, 
resulting in a decreased driving force for the recruitment of endothelial cells in order to form 
vessel networks for nutrient delivery and waste removal. Long-term culture in the bioreactor for 
3 weeks in order to match the SCID mouse experiments showed no significant difference in 
expression levels for all the angiogenic factors investigated. Thus, 1 week of culture in the 
bioreactor is adequate for the observation of variations in angiogenic factor expression due to 
culture in a perfusion bioreactor. 
 
 
Figure 6.13 Quantitative real-time PCR for angiogenic factor secretion by 143.98.2 cells cultured 




6.3.7 Angiogenic Expression Profiles for the 3D Scaffolds Cultured in the 
Bioreactor were Similar to that of the SCID Mouse Tumors 
The angiogenic factor expression profiles of the 3D scaffold tumors cultured for 1 week in the 
perfusion bioreactor were compared to the injected SCID mouse tumors in order to study the 
ability of bioreactor culture in replicating in vivo culture conditions (Figure 6.14). There was no 
significant difference in bFGF, HIF-1, and IL-8 expression observed between the two 
conditions (p = 0.19, 0.62, and 0.85 respectively) and a minimal upregulation of VEGF-A in the 
bioreactor model (p = 0.018). This indicates the bioreactor model is an effective in vitro 
representation of a solid tumor. Moreover, the average pressure measured in the bioreactor 
chambers was found to be 16 ± 1.63 mmHg, which is within the range found for the in vivo 
central 143.98.2 pressure readings for the injected tumors in Figure 6.10. The real-time PCR was 
repeated to include standard 2D culture and the combined results are given in Figure 6.15, 
showing the large difference in gene expression profiles by cells grown in 2D culture as 






Figure 6.14 Quantitative real-time PCR for angiogenic factors found the expression levels for the injected 
tumor and 1 week of bioreactor culture to be similar. **Statistically similar at p > 0.05. 
 
 
Figure 6.15 Quantitative real-time PCR for angiogenic factors showing the significant difference in 
expression levels between 143.98.2 cells grown in 2D culture as compared to the injected subcutaneous 




































































The scaffold tumors were found to have enhanced vessel density and dilation compared to the 
injected tumors, and this is similar to a study in which oral squamous cell carcinoma cells pre-
cultured on poly(lactide-co-glycolide) were harvested from the scaffold and injected into SCID 
mice [15]. The 3D pre-cultured tumors had more blood vessels than those from 2D pre-cultured 
cells, and explanted tumor lysates of the cellswith prior 3D pre-culture had increased amounts of 
VEGF-A, bFGF, and IL-8 compared to tumor lysates of 2D pre-cultured cells in that study. Thus, 
taking the results from that study with those obtained in this chapter, cells that have undergone in 
vitro 3D pre-culture are able to maintain their elevated angiogenic capacity upon implantation in 
vivo, leading to the enhanced vascularization observed in the scaffold tumors. 
 
Although Avastin treatment led to a decrease in tumor size, extensive blood vessel networks 
were still observed within the tumor (Figure 6.12). The anti-VEGF-A therapy likely had an anti-
proliferative rather than anti-angiogenic effect on the in vivo tumors, and the binding of VEGF-A 
to VEGFR-2 has been identified to promote cell proliferation and survival [256]. It should also 
be noted that, while it is often used in mouse xenografts studies, Avastin does not neutralize 
murine VEGF-A, thus, the tumor will still remain subjected to any local production of VEGF-A 
by the host stroma [257]. Given the elevated expression of IL-8 in both the 3D scaffold 
constructs and in vivo tumors and the recent reports of IL-8 having a much more important role 
in tumor angiogenesis than originally assumed [258], the findings in this study together with the 
work in Chapter 4 suggest that the efficacy of anti-angiogenic therapy would greatly benefit from 
a shift of focus from VEGF-A to IL-8-driven angiogenesis. A study on anti-angiogenic therapy 
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using the delivery of antibodies against IL-8 and VEGF-A either individually or simultaneously 
has shown that anti-IL-8 therapy leads to a greater inhibition of tumor growth compared to anti-
VEGF-A therapy, and the tumor size was even smaller when the two antibodies were used 
together [236]. 
 
The intratumoral IFP gradient observed between the periphery and center of the tumor is 
consistent with the theory that a spherical tumor mass has maximum IFP in the central region of 
the tumor, which then gradually decreases radially to the peripheral regions [208]. There exists 
an inverse relationship between the IFP measured and VEGF-A and HIF-1 expressed, and this 
has been shown in a previously published study [212] as well as in a series of clinical 
osteosarcoma cases [210], despite there being reduced oxygen tension in the center of the solid 
tumor. This relationship was seen in the injected tumors but not in the scaffold tumor, likely due 
to the lower IFP in the implanted scaffold tumors. Thus, the resulting upregulation of both HIF-
1 and VEGF-A when IFP was reduced lends further support to the theory that IFP negatively 
regulates HIF-1 and VEGF-A production.  
 
A perfusion flow rate of 143.6 µL/min was chosen for the bioreactor experiments as this was the 
lowest possible speed setting of the peristaltic pump and a flow rate of 14 to 140 µL/min has 
previously been used to simulate interstitial flow [259]. A range of higher flow rates were also 
tested, however, they caused cell detachment after prolonged culture periods and resulted in 
insufficient cells at the end of the run for analysis. The angiogenic factor profiles obtained for the 
1-week perfusion bioreactor culture were almost identical to the injected tumors (Figure 6.14). 
Thus, the bioreactor was able to adequately replicate the subcutaneous in vivo environment ex 
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vivo and has great promise in functioning as a bridge between in vitro and in vivo tumor models, 
or even as a replacement for the animal model through the use of cell types that are entirely 
human in origin, thereby circumventing some of the issues associated with animal models. In 
Chapter 3, it was not possible to fully replicate the angiogenic profile of solid tumors using the 
scaffold tumor construct without the influence of pressure and interstitial flow. There was a 
slight upregulation of VEGF-A in the bioreactor condition compared to the xenograft tumor and 
this could be due to the model consisting of purely the 143.98.2 osteosarcoma cell line. The co-
culture of U2OS with HUVECs in Section 4.3.4 resulted in a downregulation of VEGF-A, thus, 
143.98.2 cells could be co-cultured with HUVECs in the bioreactor to investigate the effect of 
co-culture on VEGF-A expression under perfusion culture. Another explanation for the 
discrepancy in VEGF-A expression could be due to the presence of mouse fibroblasts and 
endothelial cells in the tumor mass. The 143.98.2 cells should next be transfected with GFP and 
these tagged cells then implanted into the SCID mice. The tumors could then be trypsinized and 
the cells sorted with FACS for the GFP-positive cells prior to quantitative real-time PCR for 
more accurate results. 
 
6.5 Conclusions 
In this chapter, the tumors formed from subcutaneously implanted seeded scaffolds were found 
to have slower growth rates and increased HIF-1, IL-8, and VEGF-A production as compared 
to the injected tumors. Treatment of the tumors with Avastin resulted in significant reduction in 
tumor weight but did not greatly inhibit the formation of microvasculature in the tumors, 
suggesting that anti-VEGF-A therapy alone is insufficient in inhibiting angiogenesis. The IFP 
within the scaffold tumors was also lower compared to the injected tumors, and the structural 
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support offered by the scaffold led to tumors that lacked the necrotic core observed in the 
injected tumors. The lower IFP observed in the scaffold tumors also likely resulted in decreased 
suppression of HIF-1 and VEGF-A in the core of the scaffold tumors. 
 
The perfusion bioreactor used was able to establish pressure levels in the chambers that were 
comparable to the injected tumors and the resulting angiogenic factor expression profiles were 
found to be very similar to those for the injected tumors. Thus, the bioreactor model is a suitable 
approximation to the animal model, and has the potential to be used in the study of IFP on tumor 
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A novel 3D engineered tumor model was developed in this Ph.D. project through the culture of 
osteosarcoma cells in porous 3D silk scaffolds. The 3D tumor constructs were found to have 
significantly different expression levels of angiogenic factors, with IL-8 and VEGF-A in 
particular upregulated across all cell lines. Moreover, the production of IL-8, VEGF-A, and HIF-
1 was found to be comparable to the in vivo tumors, and much more relevant than the 2D 
models. 
 
The in vitro 3D model also allowed for the systematic study of the effect of co-culture on 
angiogenesis. The co-culture of U2OS with immortalized fibroblasts resulted in tumor constructs 
with increased angiogenic potential, as seen from both the real-time PCR results and Transwell® 
migration assays using HUVECs. On the other hand, co-culturing the U2OS cells with HUVECs 
led to a suppression of these angiogenic factors. Treatment of the 3D models with anti-VEGF-A 
therapy only led to a very slight decrease in HUVEC migration, while treatment with anti-IL-8 
monoclonal antibodies resulted in a dramatic drop in endothelial cell migration, thereby 
highlighting the more important role of IL-8 in angiogenesis. 
 
DNA content remained stagnant despite alamarBlue® assays indicating an increase in metabolic 
activity when the cells were cultured in the 3D scaffolds, and the cells in the 3D model were 
found to exhibit G1 arrest and, thus, had decreased proliferation rates. Cells in 3D culture were 
also found to significantly decrease their expression of cyclin B1, E2F1, and RhoA, and 
upregulate p21. This resulted in a significant decrease in susceptibility to doxorubicin, which is a 
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cell cycle specific cytotoxic drug, in the 3D model as compared to the 2D monolayer model, 
despite the expression level of MDR1 remaining unchanged in both conditions. 
 
Finally, scaffold tumors were found to have slower growth rates and increased angiogenic factor 
production as compared to the injected tumors. Similarly to the in vitro model, treatment of the 
tumors with Avastin did not greatly inhibit the formation of microvasculature in the tumors. The 
IFP within the scaffold tumors was found to be lower than the injected tumors, and this could 
have been the cause of the decrease in the suppression of HIF-1 and VEGF-A in the core of the 
scaffold tumors. The perfusion bioreactor model was successful in establishing pressure levels in 
the chambers comparable to that of the injected tumors, and there was insignificant or minimal 
difference in angiogenic factor expression profiles when compared to the injected tumors. This 
indicates that the bioreactor model is an effective in vitro representation of the in vivo 
subcutaneous tumors. 
 
Although the fact remains that 3D cultures fail to reproduce entirely the enormous complexity of 
tumor biology in vivo, specifically in the case of blood vessel supply and immune system 
response, in vitro 3D tissue models derived from tissue engineering research are very powerful 
experimental tools for cancer research. As 3D models are only able to recreate certain aspects of 
living tissues, they are not intact animals or human subjects and, thus, will be unable to 
reproduce the entire normal in vivo microenvironmental anatomy and physiology [19]. Thus, 3D 
systems must still be considered models, and any conclusions drawn from the in vitro 3D models 
may still require further testing in vivo. Regardless, they provide a potentially powerful toolbox 
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for a myriad of new applications, and a paradigm shift from the use of 2D monolayers to 3D 
models should be the key next step in the evolution of cancer research. 
 
7.2 Recommendations for Future Work 
7.2.1 Cytotoxicity Testing using Co-culture Models 
Cancer-associated fibroblasts are the main cellular component of the tumor stroma and are able 
to induce an altered ECM that provides additional oncogenic signals which enhance the 
proliferation and invasion of cancer cells [18, 21]. Thus, the co-culture models used in this study 
could potentially be used in cytotoxicity studies with doxorubicin and cisplatin. The increased 
ECM deposition due to the presence of the stromal cells would likely offer some added 
protection to the tumor cells, resulting in reduced drug sensitivity. 
 
7.2.2 Administration of Anti-IL-8 Monoclonal Antibody to the SCID Mouse 
Models 
Anti-IL-8 monoclonal antibody was found to be efficacious in the Transwell® migration assays 
carried out in Chapter 4, thus, this experiment could be repeated in the SCID mouse model to 
verify the results obtained in the 3D in vitro model. The administration of anti-IL-8 monoclonal 
antibody in conjunction with Avastin could also be carried out, and used in combination with 
doxorubicin or cisplatin to investigate the combination of anti-angiogenic therapy with 




7.2.3 Studying of the Effects of Physiological Parameters on Tumor Biology 
Using the Bioreactor 
Physiological parameters such as tumor pH, oxygen tension, and IFP were previously measured 
in heterotopic and orthotopic SCID mouse xenograft tumors [212]. These parameters could 
potentially be incorporated into the bioreactor model for a more biomimetic in vitro culture 
system. The pH could be lowered with buffers and the oxygen tension could be lowered using 
nitrogen gas displacement in the incubator. The pressure within the chambers could be increased 
by controlling the flow rate through the chamber with the incorporation of a flow control valve 
immediately downstream of the chamber (Figure 7.1). 
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APPENDIX A: Histology Protocol 
 
Specimen Preparation 
1. Fix specimen with 3.7% formaldehyde at room temperature for > 24 hours. 
2. Dehydrate with ethanol gradient for 30 min at each concentration: 70%, 95%, 100%, 
100%. 
3. Clear for 30 min in 50:50 toluene and ethanol, followed by 100% toluene. 
4. Soak specimen in 1st paraffin bath at 75⁰C for 1 hour. 
5. Transfer to 2nd paraffin bath and place in a vacuum oven (OV-11, Bio Laboratories), 
vacuum until there are no air bubbles. 
 
Specimen Embedding  
1. Use a warm mold (~50-60°C). 
2. Spray mold with mold release spray. 
3. Pour paraffin to fill the mold fully. 
4. Quickly transfer the specimen into the mold using forceps. 
5. Once the top layer has solidified, cool the paraffin mold over a cold surface. 
6. Remove paraffin block from the mold. 
 
Sectioning 
1. Shave of the excess paraffin to expose the top layer of the specimen. 
2. Soak the paraffin block in cold water for 10-15 min. 
3. Mount immediately and start sectioning at 5 µm (RM2135, Leica). 
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4. Place the section in a water bath containing 0.5% (w/v) gelatin at 40°C. 
5. Pick up the section with a glass slide and drain off the water. 
6. Place the slide on a slide warmer at 40°C overnight to dry. 
 
Staining with Hematoxylin and Eosin 
1. De-paraffin slides in 3 changes of xylene (2 min each). 
2. Rehydrate in ethanol gradient (100%, 90%, 70% & 50%, 2 min each). 
3. Transfer to tap water for 2 min. 
4. Soak in hematoxylin (5 min). 
5. Soak in tap water for 2 min. 
6. Soak in Differentiation Solution for 5 s. 
7. Soak in tap water for 2 min. 
8. Soak in eosin for a few seconds (1-3 s). 
9. Dehydrate in ethanol gradient (50%, 70%, 90% 100%, 100%, 2 min each). 
10. Clear twice in fresh xylene (2 min each). 










APPENDIX B: RNA Extraction 
 
Cells grown on Tissue Culture Plates 
Purification of total RNA for 75cm
2
 flasks: 
1. Aspirate the culture medium. Wash the cells with 5 mL of phosphate buffered saline 
(PBS). 
2. Aspirate PBS, add 3mL of HyQ Trypsin (HyClone). Place in the incubator for 2 min. 
3. Aspirate medium containing detached cells and pipette into a 15 ml polypropylene 
centrifuge tube containing 5mL culture medium. After cell detach, add medium 
(containing serum to inactivate trypsin). 
4. Centrifuge at 2000 rpm for 3 min (Centrifuge 5810R, Eppendorf). 
5. Completely aspirate the supernatant. 
6. Disrupt the cells by adding 350 µL Buffer RLT (Qiagen). 
7. Pipette the lysate directly into a Q1A shredder spin column placed in a 2 ml collection 
tube and centrifuge for 2 min at full speed. 
8. Add 1 volume of 70% ethanol to the homogenized lysate and mix well by pipetting.  
9. Transfer to an RNeasy spin column (Qiagen) and carry out RNA purification according 








Cells grown in SCID Mice 
1. Place a 30 mg sample of tissue in a 2-mL microcentrifuge tube and add 600 µL of Buffer 
RLT (Qiagen). 
2. Using a conventional rotor-stator homogenizer (TH-220, OMNI International), 
homogenize the sample until it is completely homogeneous. 
3. Centrifuge at full speed for 3 min (Centrifuge 5810R, Eppendorf). 
4. Carefully pipette the supernatant into a new microcentrifuge tube. 
5. Added 1 volume of 70% ethanol. 
6. Transfer to an RNeasy spin column (Qiagen) and carry out RNA purification according 
















APPENDIX C: Real-Time PCR Protocol 
Determine the concentration of the RNA using Nanodrop. 
1. Pipette 1.5 µL of ddH2O onto the reader. Obtain blank reading. 
2. Repeat with RNA samples. Clean with Kimwipe after each reading. 
 
cDNA Synthesis 
1. Dilute the RNA to 80 µg/mL using molecular biology grade water. 
2. Reverse transcriptase system composition (Bio-Rad Laboratories) (Total 20 µL) 
a. Diluted RNA   - 5 µL 
b. Iscript buffer   - 4 µL 
c. Reverse transcriptase  - 1 µL 
d. RNase free water  - 10 µL 
3. Program 
a. 25oC - 5 min 
b. 42oC - 30 min 
c. 85oC - 5 min 
d. 4oC - Hold 
 
Quantitative PCR 
1. Do a 10X dilution of the cDNA with ddH2O. 
2. Do a serial dilution (10x followed by 10x) 
a. Mix 10 µL forward primer, 10 µL reverse primer and 80 µL ddH2O. 
b. Mix 10 µL from previous with 90 µL ddH2O. 
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3. PCR system composition for 96-well plate (Bio-Rad Laboratories) (Total 25 µL) 
a. Primer    - 5 µL 
b. iQ SYBR Green Supermix - 12.5 µL 
c. Diluted cDNA   -  4 µL 
d. ddH2O    - 3.5 µL 
4. Seal plate and do a short spin for 20 s (Sorvall Biofuge Stratos Centrifuge, ThermoFisher 
Scientific). 
5. Program (Bio-Rad iQ5) 
a. 93oC - 3 min 
b. 95oC - 10 sec 
c. 58oC - 30 sec  35 cycles 
d. 72oC - 30 sec 
e. 95oC - 1 min 
f. 55oC - 1 min 
g. 55oC - 10 sec  81 cycles camera melt curve 
 
 
 
